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FOREWORD 
Occasionally in medicine, a single individual makes a contribution of 
such magnitude and significance that it clearly represents a new di-
rection in the field. Such is the case in this and the two subsequent 
issues of Current Problems in Surgery, which are devoted to trans-
plantation of the liver. Dr. Thomas Starzl and his colleagues, for-
merly of the University of Colorado and now of the University of 
Pittsburgh, have, by their many seminal contributions, had a great 
influence on the entire field of transplantation, but it is transplanta-
tion of the liver which has gained these scientists their widest recog-
nition. 
The operation began as an idea only 30 years ago and the seem-
ingly painful and slow steps which subsequently led from early clin-
ical trials to the current stage of development are remarkable. Today, 
the procedure is performed in a number of medical centers around 
the world, in all age groups of patients, and for a wide variety of in-
dications- a tribute to the remarkable efforts and the persistence of 
Dr. Starzl and his group. 
In the span of the three issues, Dr. Starzl and Dr. Demetris cover 
all aspects of hepatic transplantation, including the technical points 
of the replacement operation, the prevention of rejection, and the 
complications both of the operation and of the postoperative immu-
nosuppressed state. In the closing parts of this treatise, the authors 
review the newly emerging technique of multiple organ transplanta-
tion, auxilIary transplantation, and the practical limitations of the 
procedure, including organ donation and economic factors. 
This contribution is authoritative and excellent, and will surely be-
come a classic in the field. 
Samuel A. Wells, Jr., M.D. 
Editor-in-Chief 
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LIVER TRANSPLANTATION: 
A 3I-YEAR PERSPECTIVE 
PART III 
INFECTIOUS PROBLEMS IN LIVER TRANSPLANTATION 
BACTERIAL AND FUNGAL INFECTIONS 
Although liver grafts may possess some immunologic advantage, 
as discussed earlier, the practical reality is that heavy initial immu-
nosuppression and later maintenance therapy are rcquired in the 
same way as with other organs. The balance between immunosup-
pression and infectious disease control is more delicate than with 
cardiac and renal transplantation because the hepatic graft is ex-
posed to the intestinal tract through the bilimy tract or by hematog-
enous contamination from the splanchnic venous bed. The devastat-
ing role of consequent graft infection by organisms indigenous to 
the gastrointestinal IGIl tract was delincated in the early clinical tri-
als 18,470-472 as well as those in the cyclosporine era.:158• 436, 473-475 Ex-
periments in dogs performed 25 years ago provided an example of 
what now is called bacterial translocation in that the liver graft itself 
became a porous entry site for bacteria indigenous to the GI tract.47(; 
A liver damaged by rejection becomes unusually vulnerable to inva-
sion by such microorganisms. Effective immunosuppression has 
long been ['ecognized to be the only way to maintain intact tissue 
barriers and to avoid this kind of infection.18 
There has been recent interest in controlling the bacterial and 
fungal population of the GI tract with preoperative nonabsorbable 
oral antibiotics.252.477 These antibiotics selectively suppress patho-
genic gram-negative organisms and fungi but allow survival of anaer-
obes. This has been called selective intestinal decontamination. A 
typical antibiotic regimen consists of polymyxin E, gentamycin, and 
nystatin. The morbidity from infection after liver transplantation has 
been reduced vvith this approach, but the mortality has not,Z52 In 
addition to its unproved value, a practical limitation of selective de-
contamination is the inability to find a cadaveric liver at the optimal 
time ordained by the antibiotic preparation. 
Much about the subtle relationships between host defenses and 
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invasive bacteria remains to be learned in the liver transplant model. 
The host macrophage system, of which the liver is an important 
componentD:~1U is profoundly altered by transplantation. The possi-
ble role of altered graft Kuppfer's cells in contributing to 'en dot ox-
emia was discussed in an earlier section. 
Liver recipients also suffer frequently from virus infections. The re-
currence of hepatitis viruses in grafts will be discussed in the next 
section. Other virus infections occur at some postoperative time in 
the majority of liver recipients.478 
CLINICOPATHOLOGIC FEATURES OF ALLOGRAFT VIRAL HEPATITIS 
Clinical symptoms, along with the use of core biopsy, are used to 
establish the diagnosis of allograft hepatitis. In general, the clinical 
features and histologic appearance of allograft viral hepatitidies are 
identical to those observed in other immunosuppressed patients. It 
is helpful, however, to anticipate the relative time of onset of the dif-
ferent viral syndromes, since they tend to occur at characteristic 
times after liver replacement (Table 10).* The following sections are 
separated into discussions of those viruses that are classically asso-
ciated vvith hepatitis from those that are more opportunistic in na-
ture. 
Opportunistic Viruses 
The most common viral pathogens in the opportunistic categOIY 
that cause allograft hepatitis belong to the herpes family: CMV, HSV 
types 1 and 2, varicella-zoster (VZ) virus, and EBV. Another cause of 
allograft hepatitis not commonly seen in the general population is 
adenovirus (ADV). The following are presented in order of frequency. 
TABLE 10. 
Peak Incidence of Graft Syndromes vs. the Time After Transplant 
Viral Syndromes 
Cytomegalovirus 
Herpes simplex 
Epstein-Barr 
Adeno;irlls 
Hepatitis H 
Hepatitis A 
nun-A, nun-B hepatitis 
Time After Transplant 
3-8 wk, often after treatment of rejection 
Ally timc after transplant 
Most common in first 2 mo. but may occur anytime thereafter 
3-4 wk after transplant. 
Onset usually after 4-6 wk, and graft remains infected 
'10 experience to date 
Usually after 4 wk 
'Table 1 appears in Part I; Tables 2-9 appear in Part II. 
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Cytomegaloviral Hepatitis 
FIG 56. 
Characteristic histologic features of CMV 
hepatitis include Kupffer's cell hypertrophy, 
spotty lobular necrosis (A, arrows) 
accompanied by microgranulomas or 
microabscesses (8); inclusions can be 
found in nearby cells (8, arrow). 
Cytomegalovirus inclusions (C) can be 
found in any cell within the liver, including 
the biliary epithelium (arrow), where it has 
been associated with loss of bile ducts 
(see text) . 
The most common serious infections are with Cl'vfV, which 
can cause lesions in many organs.353, 354. 478-480 Cytomegalovirus 
is the most common cause of postoperative graft hepatitis and 
is seen most frequently between 3 and 8 weeks after trans-
plant.353, 354, 478-480 Protection from serious CMV infection has been 
reported with hyperimmune globulin.481 Recovery is the rule if im-
munosuppression is lightened and especially if therapy is given with 
ganciclovir (Gancyclovir).479,482 However, Cl'vfV strains resistant to 
ganciclovir have been reported recently483 The onset of Cl'vfV is often 
temporally related to episodes of rejection, where the patient has 
just received additional immunosuppressive therapy for an acute 
cellular rejection episode a53, 354,478-480 
ClinicalJy, patients usually present with a low-grade fevel' and 
mildly elevated liver injury test results . Leukocytopenia, diarrhea, GI 
ulcers, and respiratory symptoms are not uncommon.353, 354.478-480 
The diagnosis of liver involvement is confinned by needJe biop-
sy.144.145,353 
CytomegaJoviral hepatitis is characterized by lobular alterations 
(Fig 56) .*144.145,353 Any cell type of the liver may be infected, and 
'Figures 1-42 appear in Part I; Figures 43-55 appear in Part ll. 
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those that are may demonstrate cytomegalic change, intranuclear 
eosinophilic inclusions sUfTounded by a halo, anciJor small baso-
philic cytoplasmic inclusions. These foci are often infiltrated with 
clusters of inflammatory cells, consisting of neutrophils, macropha 
ges (microabscesses and microgranulomata), or both. Other lobula 
alterations include mild Kupffer's cell hypertrophy. Significant lobu 
lar disarray, massive or submassive necrosis, or even severe live I 
damage ti'om CMV alone is rare. Recognition of any of these changes 
should prompt a careful search for viral inclusions, the use of immu-
nohistochemical stains for the detection of the CMV antigens, or 
both. 
Tissues containing rapidly dividing cells, such as young granula-
tion tissue, proliferating cholangioles, edges of infarcts, and ab-
scesses or other defects are fertile soil for CMV growth 1 44, 145 When 
such tissue is encountered, a more careful search of CMV is war-
ranted.144.145 
Finally, CMV can be associated with a plasmacytoid or blastic in-
filtrate (or both) similar to that seen in EBV hepatitis (unpublished 
observations) . Cytomegalovirus inclusions are not usually detected 
in such cases. Differentiation from rejection and lymphoproliferative 
disease associated with EBV may be difficult and is based on careful 
microscopic examination and immunohistochemical stains to detect 
viral antigens. The clinical profile and various hematologic parame-
ters are also helpful. 
Recently, CMV has been implicated in the pathogenesis of the van-
ishing bile duct syndrome (VBDS)4(>0 Compatibility between the do-
nor and recipient at the DR MHC locus, along vvith mismatching 
at the class I locus and CiVIV infection have been iden tined as in ter-
dependant risk factors for the development of bile duct loss45",4(;0 
The Cambridge group has suggested that MHC-restricted antigen 
presentation of viral antigens or mismatched class I MHC antigens 
by DR-compatible bile duct cells is responsible for this obserVa-
tion :~SM 
Herpes Simplex and Varicella-Zoster Hepatitis 
Both subtypes of HSV (1 and 2) and the VZ virus have been identi-
fied as causes of liver allograft hepatitis. Signs of graft infestation 
have been seen as early as 3 days after transplant and may occur 
any time thereafterl4D~K 354. 4114 The clinical presentation with the HSVs 
includes fever, fatigue, and body pain combined with serologic evi-
dence of hepatic injUlyl44, 145,354 Cutaneous manifestations mayor 
may not be present. With the VZ virus, allograft involvement may be 
detected several days prior to the eruption of cutaneous vesicles 
typical of this disorder. Untreated, any of these viruses may rapidly 
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A, the HSV and the VZ VIrUS produce 
simitar lesions in the liver allograll. 
characterized by targe areas of 
coagulative-type necrosis (arrows) B, 
multinucleated cells may be seen at the 
periphery 01 the lesion, and occasionally 
characteri st ic Cowdry type A inclusion 
bodies are Identil ied like those shown in 
C (arrows) . 
lead to massive hepatic necrosis. Therefore, eady recogmtlOn on 
needle biopsy is particularly crucial since effective medical therapy 
(acyclovir) is available. 
Microscopically, all three viruses produce similar graft pathology 
(Fig 57) 144, 145, D~B4 They are characterized by circumscribed areas of 
coagulative necrosis, shovving no respect for the lobular architec-
ture, Ghosts of hepatocytes intermixed with neutrophils and nuclear 
debris are seen in the center of the lesions, More viable hepatocytes 
are seen at the periphely, some of which may contain ground glass 
nuclei or characteristic inclusion bodies, Multinucleated cells are 
also occasionally present. Immunoperoxidase stains for various viral 
antigens confirm the diagnosis when the pathologist is unsure on 
the basis of the hematoxylin-eosin stains alone, 
Epstein-Barr Virus 
Consequences of primary infection or reactivation of the EBV after 
transplantation run the gamut fmm an infectious mononucleosis 
syndrome as seen in the general population4BS to severe life-threat-
ening lymphoproliferative disease similar to patients with the X-
linked lynlphopmliferative disorder4K'i or acquired immunodefi-
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ciency syndrome (AIDS).4tl7 Lymphoproliferative tumors (B-cell lym-
phomas) have been seen with all kinds of transplantations but most 
frequently in liver recipients3S5,488-491 and especially in infants and 
children, in whom the risk over the first 2 years after transplantation 
may be as high as 10% .355.492 The liver graft itself is frequently in-
volved. The most effective treatment measure for any of the EBV syn-
dromes is discontinuance or reduction of immunosuppression,48tl to 
which antiviral therapy with acyclovir should be added .493 Regres-
sion of the symptoms, laboratory abnormalities, and lymphomas 
usually, although not invariably, follows reduction of immunosup-
pression whether or not acyclovir is given ,488, 490, 491 This effect 
may be achieved even though the hepatic graft is not rejected. The 
regression of these lymphomas, some of which are monoclonal , 
when the recipient immunologic responsiveness is allowed to re-
cover is thought to be an example of immunologic surveillance in 
humans .488 
Clinical signs and symptoms of recipients with EBV syndromes at 
the more benign end of the spectrum are similar to those seen with 
infectious mononucleosis, although atypical presentation in the 
form of fever, rashes, and joint and jaw pain are not uncommon. 
Liver enzyme levels are usually only modestly elevated, but occa-
sionally significant damage and even submassive or massive necro-
sis may be seen. Those recipients who develop tumors present 
clinically with constitutional symptoms similar to those just de-
scribed in addition to those related to organ system involvement 
with tumor488-491 Atypical lymphocytosis in the peripheral blood 
smear is invariably present in all patients. The diagnosis of allograft 
involvement is confirmed by needle biopsy evaluation of the graft. 
Like the variety of clinical disorders, involvement of the liver by 
EBV-associated disorders also runs the histopathologic gamut from 
typical monohepatitis as seen in the general population to submas-
sive or massive hepatic necrosis145 or involvement by tumor, com-
prised of malignant lymphoid cells similar to those seen in immuno-
blastic lymphomas (Fig 58). Cases resembling lymphomatous in-
volvement of the liver may be difficult to differentiate from acute cel-
lular rejection 145 since subendothelial infiltration of the portal veins 
along with focal bile duct damage may be present. Usually these are 
not as severe or as widespread as those seen with rejection. The key 
to the diagnosis is the monomorphic and atypical appearance of in-
filtrative cells in the EBV-related disorders. Immunohistochemical 
staining to detect EBV viral antigens can be performed but reqUires 
frozen tissue . Immunophenotypic analysis of the infiltrative cells in 
EBV-related disorders usually demonstrates a great number of 
non-T cells, whereas in acute cellular rejection, the T cells predom-
inate. 
Biopsy of enlarged lymph nodes (most common) or other organs 
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FIG 58. 
The EBV causes a spectrum of pathologic lesions in the liver, ranging from mild lobular 
hepatitis with sinusoidal lymphocytosis (A) to granulomatoid collections (8) of immuno-
blastic lymphocytes, which can be associated with hepatocyte necrosis (C, arrow) . Ep-
stein-Barr virus-driven Iymphoproliferative lesions in the liver (0) are characterized by a 
monomorphic infiltrate that overruns the normal architectural landmarks. (From Demetris 
AJ, Jaffe R, Starzl TE: Patho/ Annu 1987; 22:347-386. Used by permission.) 
infiltrated by tumor is also used to establish the diagnosis of an EBV-
related disorder. In the nodes, the changes vary from those seen 
with infectious mononucJeosis494 to a histology indistinguishable 
from immunoblastic lymphoma 489 Immunohistochemical and light-
chain immunoglobulin gene rearrangement analysis are used to es-
tablish the cJonality of the tumors, if present:~Uo- 49 1 
Adenoviral Hepatitis 
Allograft hepatitis due to the ADV has been restricted to primarily 
the pediatric population, although more recently an unequivocal 
case in an adult has been identified.356, 357 Adenovirus usually oc-
curs within a very narrow time frame, namely, 20 to 30 days after 
transplant, and the patients present with fever and elevated liver in-
jury test results.357 To date) almost all of the cases of ADV in the 
transplant population have been caused by viral subtype 5.3 .'>7 How-
ever, other viral subtypes (2) 11, and 16) have been associated vvith 
hepatitis in the general population and could be expected to infect 
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FIG 59. 
A, the ADV causes typical granulomas in the liver . Immunoperoxidase stains can be help-
ful if one cannot identify the inclusion bodies (a rrows) . B, at the periphery of the granu lo-
mas, infec ted cells with intranuclear Inclusions appear smudgy. (From Demetris AJ , Kaki-
zoe S, Oguma S Pathology of liver transplantation , in Williams JW led] Hepatic Trans-
plantation . Philadelphia, WB Saunders Co (in press]. Used by permission.) 
allografts 495 The diagnosis is made on needle biopsy sampling of 
the organ,357 after which immunosuppression should be temporarily 
stopped. 
Histologically) granulomatoid collections of histiocytic cells are 
randomly located throughout the parenchymal (Fig 59). Hepatocyte 
necrosis may be detected but usually is less severe than that seen 
\-vith HSV. Characteristic "smudgy" intranuclear inclusions can be 
identified in hematoxylin-eotiin-stained sections) but experience is 
required to be confident of the diagnosis without the use of special 
stains . In infected ce]]s, the chromatin is crowded toward the nu-
clear membrane) which imparts a muffin-shaped appearance to the 
nucleus. Immunohistochemical stains are confirmatory. 
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HEPATITIS VIRUSES 
HEPATITIS B VIR US 
Viral hepatitis type B in the posttransplant period is restricted 
largely to those patients who carried the virus prior to transplanta-
tion, although a few patients have acquired an infection, presumably 
as a result of blood transfusion . Provision of a nevv liver usually, 
but not always, lowers the titer of the virus, as measured by the sur-
face antigen,496,497 but return of the carrier state is almost univer-
sal.498-S02 In spite of this generalization, some chronic carriers have 
apparently cleared the virus after transplantation499-so3 vvith passive 
immunoprophylaxis . In our experience, those chronic carriers who 
have cleared the virus have been E antibody positive and E antigen 
negative, although this serologic profile is no guarantee that infec-
tion vvill not recur. Among those recipients who become reinfected, 
a small percentage vvill develop a carrier state and experience long-
term s urvival vvith minimal liver dysfunction. Recapitulation of the 
original chronic aggressive hepa titis jeopardized the recovery of 
many of the recipients.48D -498, 501 Delta agent coinfection is an 
additional confounding factor and recurs along vvith the B vi-
rus 4S17 . 500, 501 Reinfection of the allograft after transplantation for 
acute fulminant hepatitis B is less certain, vvith several patients ex-
periencing long-term sUIvival vvith viral immunity.487,498 The survival 
with acute disease and fulminant hepatic failure has been accept-
able, although less favorable vvith chronic disease (Fig 60). 
In those who develop HBV disease after liver replacemenc the on-
FIG 60. 
ICO -,- -- - - - - --- --- --- --- -, 
20 
ACUTE HBV 
(HBsAg+) 
-e-
CHRONIC HBV 
(HBsAg+) 
-8-=-
o4I---~---~--_Kr_---~---K_~ 
o 12 24 36 .18 60 
MONTHS AFTER TRANSPLANTATION 
Patient survival (life table method) after liver transplantation with cyclosporine- prednisone 
for 65 adults with chronic B vi rus hepatitis compared with 13 adults with acute B virus hep-
atlil s. 
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set of symptoms usually occurs 6 to 8 weeks after transplantation. 
The presentation varies from asymptomatic elevations of liver injury 
test results to nausea, vomiting, jaundice, and hepatic failure. The 
clinical syndrome, therefore, is not significantly different from viral 
hepatitis as seen in other immunosuppressed hosts. Serologic eval-
uation and needle biopsy of the graft confirm the diagnosis. 
Pathologic identification of acute hepatitis B as a cause of dysfunc-
tion rests on the recognition of preferential lobular alterations in the 
absence of significanl inflammatory cell damage to bile ducts, arter-
ies, and venular endothelia 487 However, the pathologic appearance 
of HBV in the allograft is as varied as the complete spectrum of 
acute and chronic viral hepatitis as seen in the general population 
(Fig 61)]45 Simply stated, viral hepatitis in the liver allograft looks like 
viral hepatitis in other livers except for a relative paucity of inflam-
mation in some cases, even vvith severe clinical manifestations and 
pathologic changes. 
FIG 61. 
Hepatitis B virus infection of the allograft causes pathologic lesions simi lar to those seen In 
the general population and in other immunosuppressed hosts. In A there is an acute hep-
titis vvith lobular disarray, hepatocyte ballooning , and necrosis . B, in chronic active B viral 
hepatit is in the allograft, a portal infiltrate with active piecemeal necrosis (arrow indicates 
intact bile duct) (C, straight arrow) and preservation of the bite ducts (curved arrow) are 
the identifying features. D, the eventual outcome of many cases with chronic active hepa-
titi s after transplantation is graft failure or cirrhosis , which may occur with surprising rapid-
ity (see text). 
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The natural histOIY of hepatitis B infection of the allograft liver is 
becoming clearer. In our series of 59 patients who received allografts 
because of HBV disease, pathologic follow-up was available in 39 of 
46 recipients who survived for more than 60 days. Thirty-foul" of 
these :m patients had histologic evidence of recurrent hepatitis n in-
fection, disease, or both. 
A veIY typical sequence of pathologic changes was observed in 
these specimens. The first evidence of recurrent hepatitis B infection 
was the detection of hepatitis H core antigen in the cytoplasm of he-
patocytes several weeks after transplantation. Little pathologic 
change was detected at this time. Several weeks thereafter, mild lob-
ular disarray, hepatocyte swelling, and mild spotty acidophilic ne-
crosis with regenerative change coincided clinically with the onset 
of elevated liver injUIY test results and signaled the developmerit of 
disease activity. Most of the specimens at this time had the appear-
ance of a mild acute hepatitis as seen in the general population ex-
cept for a relative paucity of lobular portal inflammation. 
Follow-up of these patients over several weeks to greater than 5 
years revealed several clinicopathologic "syndromes." Six of the pa-
tients experienced a syndrome of unresolved lobular hepatitis, and 
five settled into a clinicopathologic profile resembling chronic can'i-
ers with little disease activity. Eighteen others developed chronic ac-
tive hepatitis, and four of these became cirrhotic, 1.5 to 5 years after 
transplant. A fifth patient rapidly became cirrhotic 147 days after 
liver replacement without any evidence of intervening chronic active 
hepatitis after transplantation. Follow-up of the few patients who 
have apparently cleared the virus with no serologic or histologic ev-
idence of recurrent n viral infection of the liver revealed nonspecific 
changes in three, non-B chronic active hepatitis in one and acute 
cellular rejection, which responded to bolstered immunosuppres-
sive therapy, in the remaining patient. 
It is not always easy for the pathologist to distinguish between re-
jection and hepatitis as a cause of malfunction. The most useful fea-
ture overall used to differentiate these two causes of malfunction is 
the focus of lymphocytic damage. The bulk of the injUIY associated 
with acute HBV is directed at hepatocytes and is recognized as lob-
ular alterations. Acute rejection, on the other hand, is directed at 
structures within the portal tracts. In chronic hepatitis, portal in-
flammation is present, and lobular alterations may be minimal. In 
these cases, one has to determine if piecemeal necrosis or bile duct 
destruction is the more prominent feature. It must be stressed that 
an overall assessment of the entire biopsy specimen with careful ex-
amination of each portal tract must be performed. Individual cases 
may be quite difficult since both bile duct damage and significant 
piecemeal necrosis may be present. It has been our policy that if a 
significant amount of duct damage is detected, regardless of the 
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presence of piecemeal necrosis, a diagnosis of rejection made. A 
therapeutic or diagnostic clinical trial of immunosuppressive ther-
apy is then initiated. This approach seems prudent, considering the 
fact that reductions of immunosuppression during hepatitis B infec-
tion may result in fulminant liver failure. 
NON-A, NON-B HEPATITIS 
Although precise identification of at least one of two viruses 
responsible for non-A, non-B hepatitis has just recently been 
achieved (hepatitis C),504 it is undoubtedly a cause of allograft hepa-
titis.I44, 145,505 Episodes in patients with cryptogenic cirrhosis, in 
those with unrelated disorders, and in patients who were thought to 
have the disease prior to transplantation have been identified. It may 
therefore be recurrent or develop de novo. The onset of symptoms 
and laboratory abnormalities usually appear after 6 weeks. The clin-
ical presentation is as variable as that seen in the general popula-
tion: mild asymptomatic elevation of liver injury test results to mas-
sive hepatic necrosis. Bone marrow aplasia, which also can compli-
cate milder attacks of non-A, non-B hepatitis not requiring liver 
transplantation,5os,507 has been obseIVed in children a few days or 
weeks after liver replacement.50s,509 Four of the nine patients with 
marrow aplasia survived, usually with slow recovery of the he-
matopoietic system.50S, 509 At present, the diagnosis is based largely 
on biochemical evidence of liver injury combined with the histo-
pathologic profile, although supporting serologic data may soon be-
come available. 
The histopathologic appearance of presumed non-A-, non-B hep-
atitis may be as varied as that described for hepatitis B earlier. Nee-
dle biopsy specimens from patients thought to be infected during 
the acute stages show mild Kupffer's cell hypertrophy, spotty acido-
philic necrosis of hepatocytes, and a relative paucity of inflamma-
tion. However, lobular disarray, mixed inflammatory cell infiltration, 
hepatocyte ballooning, and necrosis, which may be bridging, have 
also been seen. The disease may also recur in a more fulminant 
fashion, as was experienced with two patients in Pittsburgh, where 
the clinical profile and histologic appearance of the failed graft was 
remarkably similar to the native organ. Later, features of chronic per-
sistent or active viral hepatitis are not uncommon (Fig 62). 
Pathologically, in acute disease the diagnosis is based largely on 
the lobular insult and is usually not difficult to differentiate from re-
jection. In chronic disease where the histologic appearance is that of 
chronic persistence or active hepatitis, it may be hard to differenti-
ate from an indolent rejection reaction. It has been our policy that if 
there is evidence of significant duct damage, rejection is considered 
present.145 
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FIG 62. 
The histologic appearance of presumed non-A, non-B viral hepatitis in the allograft is sim-
ilar to the type B virus. In this case a ch ronic active hepalitic lesion is seen, (From Deme-
tris AJ , Kakizol S, Oguma S: Pathology of liver transplantation , In William JW [ed]: Hepatic 
Transplantation Philadelphia, WB Saunders Co [in press] , Used by permission ,) 
HEPATITIS A VIRUS 
Although fulminant hepatitis A virus has been an indication for 
liver replacement, it has not as yet been identified as the cause of 
allograft dysfunction . Based on these obselvations, we expect that it 
may appear quite similar clinically and histologically to that seen in 
nongrafted livers, 
THE PATHOLOGIST'S VIEW OF BILIARY TRACT COMPLICATIONS 
Anastomotic breakdown, necrosis, strictures, ascending infection, 
and obstruction can affect the allograft biliary tree ,84-90.!')3 Although 
these complications are not uncommon in isolation, they often re-
flect arterial pathology since the bilialY tree is dependent solely on 
the hepatic artery for its blood supply.l<16 Most often the diagnosis of 
biliary complications is made on the basis of clinical symptoms and 
the results of radiologic procedures such as ultrasonography and 
cholangiography (see previouslyJ.1>4 - 90 In addition, during the early 
postoperative period, most pati ents have a percutaneous T tube in 
place that permits ready access to the biliary tree for radiologic pro-
cedures and assessment of bile flow, 
Needle biopsies are less useful than radiologic evaluations fOl' the 
diagnosis of large biliaJY tract disorders becallseof the relative noo-
specificity and insensitivity of eady histologic findings 144.145 How-
ever, vvhen access to the biliaJY tree is I'es tricted, (late posttransplant 
period ), biopsies may be more valuable as a screening tool. Biliary 
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The histologic manifestation of biliary tract complications in the allograft are similar to 
those In nonallografted livers. The most Important of these features is the neutroph ilic pre-
dominance of the portal infiltrate in the absence of reactive biliary epithelial cell changes, 
as shown in th is case of acute cholangitis (A). When the biliary tree is obslructed , peri-
duclal edema accompanies the acute portal inflammation, and cholestas is is present In 
the lobules (B), Fistulas between Ihe biliary tree and Ihe vasculature are recognized by Ihe 
presence of RBCs in bile ducts (C, arrow) or bile concretions in blood vessels (0, arrow). 
(From Demelris AJ , Kakizol S, Oguma S. Palhology of liver transplantation , in Will iam JW 
red] Hepatic Transp lantation Philadelphia, WB Saunders Co [in press]. Used by permis-
sion .) 
tract complications that have been recognized histologically include 
duct stricturing, obstruc tion, acute cholangitis, and biliary-vascular 
fistulas J 44 ,145 The histologic features of these complications are 
identicaJ to those seen in the nonaJJograft liver (Fig 63), which in-
clude a predominantly neutrophiliC portal infiltrate, periductaJ 
edema, intraepithelial and intraductal neutrophils, mild ductular 
and cholangiolar proliferation, centrilobular hepatocanalicular 
cholestasis, and small clusters of neutrophils scattered throughout 
the lobules. Although acute cellular rejection is included in the 
pathologic differential, bilialY trac t disorders most commonly are as-
sociated with a neutrophilic and eosinophilic portal infiltrate, 
whereas rejection shows a predominance of mononuclear cells in 
the porta] tracts. 
Recognition of biliary-vascular fistulas may be first noticed by the 
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pathologist on needle biopsies and requires alertness to the abnor-
mal presence of RBCs in bile duct lumens or, conversely, bile con-
cretions in blood vessels (see Fig 63). Radiologic localization of the 
abnormal communication, followed by corrective surgery or retrans-
plantation, is the usual course of events. 
SEPSIS 
Infection of the blood, especially with gram-negative organisms, 
can cause allograft dysfunction, which is usually manifested as jaun-
dice. Histologic alterations are also observed in the graft as a result 
of sepsis (endotoxemia) and are identical to those seen in nonal-
lograft livers.51o These changes include cholangiolar proliferation 
with bile plugging, acute cholangiolitis usually without cholangitis, 
and hepatocanalicular cholestasis. Kupffer's cells are often hypertro-
phied, and small clusters of neutrophils can be observed in the lob-
ules?44,145 
DIFFERENTIAL DIAGNOSIS OF DRUG AND TOXIC INJURY 
Drug and toxic injury to the allograft liver are difficult to identify 
with certainty. The patients receive many potential hepatotoxic 
drugs and are subjected to other therapeutic maneuvers that may 
damage the liver. Therefore, if one strictly adheres to criteria for or-
gan specific toxicity, it is extremely difficult to incriminate any agent. 
Regardless of these difficulties, erythromycin, prolonged peripheral 
alimentation, high-dose steroids, and azathoprine have been 
strongly suspected as causes of allograft malfunction.144,145 One 
might expect the allograft liver to behave similar to nongrafted livers 
in regard to drug toxicities, unless an MHC-restricted immunologic 
reaction is involved. 
INFLUENCE OF HISTOCOMPATIBILITY 
Histocompatibility leukocyte antigen (HIA) or MHC compatibility 
has been shown to either improve patient survival or reduce the on-
set or incidence acute rejection in kidne~11 and heart allografts.512 
Data collected by Markus and associates concerning the role of HIA 
matching in liver transplantation were less clear cut.513 No patient 
survival advantage was observed for HIA compatibility. By contrast, a 
statistically significant penalty in terms of survival was detected 
when either the A, B, or DR locus was matched. Although rejection 
as a cause of graft failure was more common when DR mismatching 
was present, other causes of patient death or graft failure were even 
more common when either class I or II loci were matched. Primary 
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nonfunctioning of the new liver was particularly common in DR-
matched grafts. However, the diagnosis "primary nonfunction" is 
somewhat of a wastebasket category, which often includes preserva-
tion injUIY, antibody-mediated rejection, vascular thrombosis, surgi-
cal misadventures, and cardiovascular instability in the donor or re-
cipient. Markus and associates suggested that MHC compatibility 
may provide the ideal setup for recurrent disease since some of the 
immunopathologic mechanisms important in the native diseases arc 
thought to be MHC restricted:SJ:l Alternatively, they suggested that 
the alloresponse itself may be MHC restricted. Donaldson and col-
leagues proposed a similar hypothesis.459 They found that DR-
matched but A and/or B locus-mismatched grafts were more prone 
to develop the vanishing bile duct syndrome (chronic rejection). 
They suggested that induction of DR antigens on bile duct cells en-
abled these cells to act as antigen-presenting cells, presenting the 
mismatched class I antigens in an MHC-restricted fashion to recipi-
ent effector cells. 
There are many possible explanations for the somewhat peculiar 
observations made with respect to HLA matching and liver allograft 
outcome. Like other allografts, livers seem to experience a lower in-
cidence of rejection when the DR locus is matched. Paradoxically, 
there does not appear to be a patient or graft survival advantage for 
DR or class I matching. This may be due to graft loss or patient 
death from causes other than rejection (e.g., technical mishaps and 
infection). A higher incidence of recurrent native disease in HIA-
matched patients may be a possibility, since cellular "immune" 
mechanisms arc thought to playa prominent role in native hepatic 
disease. This contrasts to most cardiac and renal diseases for which 
transplantation is performed, where cellular immunity is not 
strongly implicated. This argument is appealing because the im-
mune damage purportedly mediated by T lynlphocytes in liver dis-
eases such as hepatitis B is thought to be MHC restricted. However, 
the pathogenic mechanisms responsible for many native liver dis-
eases have yet to be elucidated. Furthermore, recurrent disease 
must be proved after liver grafting, which is not an easy task. H.ather 
than to continue speculation, reanalysis of the data after collection 
of a much larger patient population seems wise. 
CANDIDACY, ORIGINAL DISJ:;;ASJ:;;, AND OUTCOME 
Tn spite of the diversity of etiologies, manifestations, and variability 
of technical problems with different diseases, the survival curves 
have not been greatly influenced by the original diagnosis with the 
exceptions of fulminant hepatic failure, chronic active hepatitis due 
to B virus, and liver malignancies (Fig S4FK4~luI 499, 514-51, These obser-
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FIG 64. 
Comparison of patient survival rates (life table method) after liver transplantation in adults 
receiving cyclosporine-prednisone for HBsAG-posltive postnecrotic cirrhosis (66 cases). 
primary hepatobiliary cancer (89 cases), fulminant hepatic failure (48 cases), and other 
nonmalignant indications for liver transplantation (827 cases). 
vations, which have been extensively documented, are analogous to 
those in renal transplantation where the original kidney disease has 
been said to have little influence on the outcome. 
However, the foregoing summary is oversimplified, which could 
degrade the value of information summarized in the following pages 
that covers not only the influence of disease on outcome but also 
many other factors, including the severity of the disease at the time 
of the liver replacement, issues of organ supply, and the role of so-
cioeconomic factors. Thus, the serious student of hepatology, liver 
surgery, and liver transplantation is urged to read this section and 
not skip to the next one. 
The medical issues of transplant candidacy are relatively clear. If a 
patient has end-stage nonmalignant liver disease that does not recur 
in the hepatic graft, there is little debate about the logic in principle 
of transplantation (Table 11). Transplantation is more debatable if re-
currence of a nonneoplastic disease is a predictable problem. The 
most controversial indication for liver transplantation is for the treat-
ment of hepatic malignancies. However, none of these broad appli-
cations can be arbitrarily excluded from future trials because there 
is such heterogeneity in each of these three categories. 
In adults, the diseases most commonly represented have been 
postnecrotic cirrhosis, primary biliary cirrhosis, alcoholic cirrhosis, 
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TABLE 11. 
Indications 1'01' Liver Transplantation in 43S Pediatric and 1,031 Adult Palients 
Pediatric Adult Total % 
Acute hepatic failure 23 48 71 4.8 
Postnecrotic cirrhosis 44 361 405 27.6 
j\lcoholic cirrhosis 113 113 7.7 
Biliary atresias 236 5 241 16.4 
Congenital hepatic 6 4 10 0.7 
fibrosis 
Cystic fibrosis 3 4 7 0.5 
Inborn eI1'OI"S of 75 52 127 S.6 
metabolism 
Familial cholestasic 16 16 1.1 
syndrome 
Neonatallgiant eel!) 7 7 0.5 
hepatitb 
PrimaIY biliary cirrhosis 210 210 14.3 
Secondary bilimy cirrhosis 9 13 22 1.5 
Primary sclerosing 4 "9 103 7.03 
cholangitis 
Budd-Chiari syndrome 2 21 23 1.6 
Benign tumors 4 9 13 0." 
Primary liver cancer 8 59 67 4.6 
Bile duct cancer 18 18 1.2 
Metastatic cancer 12 12 0.8 
Liver trauma 1 2 3 0.2 
Secondary sclerosing 1 1 0.1 
cholangitis 
Total 4:-18 1,0:>1 1,469 100.0 
sclerosing cholangitis, inborn errors of metabolism, and a heteroge-
nous group of hepatic malignancies (see Table 11). The 5-year life 
survival CUIves of the principal benign adult diseases are shown in 
Figure 65. There has been little variability of sUlvival with these be-
nign diagnoses in contrast to the poorer results in the neoplastic 
group (see Fig 64). 
More than one half of the pediatric recipients have had biliary 
atresia, with inborn metabolic errors a distant second.514• 516-526 Sur-
vival in the biliary atresia patients is inferior to the other categories 
(Fig 66). The principal mortality has been perioperative and has been 
related to technical difficulties caused by earlier Kasai operations. 
The experience reflected in these life sUlvival CUlves will influence 
future case selection. However, other factors could be singly or cu-
mulatively even more important for prognosis than the original diga-
nosis. Judgment about what constitutes candidacy has been in a 
state of flux since the first clinical attempts in 1963, and the time is 
not yet ripe to freeze guidelines. 
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Patient survival rates (life table method) after liver transplantation using cyclosporine-ste-
roids for the major indications in adults (18 years of age or older at the time they received 
their first transplant). Included are 296 cases of postnecrotic cirrhosis (excluding HBsAG-
positive patients), 210 cases of primary biliary cirrhosis, 113 cases of alcoholic cirrhosis, 
99 cases of primary sclerosing cholangitis, and 52 cases of inborn errors of metabolism. 
MALIGNANT LNER DISEASE 
In the original efforts at clinical liver transplantation,18 all of the 
patients whose reason for transplantation was primary hepatic ma-
lignancy and who survived the perioperative period died within 13 
months of recurrent tumor. Smaller incidental malignancies be-
haved differently. The longest survivor in the world today received 
her new liver at the University of Colorado on January 22, 1970 for 
biliary atresia. The excised liver contained a 3-cm hepatoma. That 
little girl, 3 years old at the time of operation, will complete her 20th 
postoperative year in a few months. She is married to a United States 
Marine and lives in Okinawa. The same observations with incidental 
malignancies have been made many times since?86,527 
In spite of numerous disappointments, liver transplantation as a 
means to extend resectability limits for hepatic neoplasms is still be-
ing probed by many transplantation teams, often in combination 
with adjuvant chemotherapy or other experimental treatment proto-
cols.528-53o The percenta~e of tumor cases in large programs ranges 
from 4% to 34% .514, 518, 519, 531-534 It has been about 5% at the Colo-
rado-Pittsburgh program (see Table 11). 
Although strenuous efforts are made beforehand to rule out 
metastases, a high rate of recurrence of all kinds of hepatic malig-
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Patient survival rates (life table method) after liver transplantation uSing cyclosporine-ste-
roids for the major Indications in children «18 years of age when they received their first 
transplant). Included are 235 cases of biliary atresia, 75 cases of inbom errors of metab-
olism, 44 cases of postnecrotic cirrhosis, and 8 cases of primary hepatobiliary cancer, 
nancies continues to be seen after total hepatectomy and trans-
plantation.* i\letastases have had a tendency to home to the new 
li\'er.18,5:H Death from tumor recurrence has been reported as early 
as 3 months, but the principal mortality has been between 6 and 36 
months [Fig 67). Small incidental malignancies that develop in cir-
rhotic livers usually do not recur, but extensive cancers recur in the 
majority of cases.527, 5:n, 534, 5:15 The results also are influenced by the 
tumor cell type IFig 68), presence of hilar lymph node metastases, 
and presence or absence of underlying liver disease.!i', ,199, 52" 531. 33(; 
Fibrolamellar hepatoma, a slowly growing relatively uncom-
mon hepatocellular carcinoma .vith distinctive histopathologic fea-
tures,53,,538 is a "favorable" malignancy, and long survival has been 
accomplished even of patients with huge tumors that have invaded 
the diaphragm.67, 527. 531,53·1,539 Most authors have reported poor re-
sults with duct cell carcinomas, including the small Klatskin tumors 
that are located high in the hepatic hilum,527, 530,,:12, 5:14 but a recent 
German experience has been IllOre optimistic,5:Hi Recurrence has 
been exceptionally common in patients with conventional hepato-
cellular carcinomas.52' Epithelioid hemangioendotheliomas54o oc-
cupy an intermediary position in that survival for at least 2 years has 
been achieved in more than one half of reported patients,53!' 541 
\Vhether to continue treating primary hepatic malignancies is con-
*References 18,4,)9,514,527,531, S:H-S:J6. 
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FIG 67. 
Patient survival rates for (life table method) after liver transplantation for primary hepato-
cellular cancer compared with liver transplantation for nonmalignant diseases but with an 
Incidental hepatocellular carcinoma discovered on subsequent pathologic examination of 
the removed native liver. 
troversial. It is difficult to resist continuing these efforts for the treat-
ment of hepatic malignancies in carefully screened recipients) not 
only because there is a chance of success but because there is so much 
potential information to be acquired about the biologic behavior of 
these tumors and the influence on them of immunomodulation and 
chemotherapy. Even a few patients with metastatic liver disease have 
benefited from liver transplantation,514. 529, R~~lI 535. 542. 543 particularly 
when the primaries were neuroendocrine in origin.514, 535, 5;16 In one 
remarkable case, a patient with multifocal liver metastases from a 
carcinoma of the breast was successfully treated with chemother-
apy, autotransplantation of the bone marrow, and liver transplanta-
tion.529 Ultimately, she developed recurrences; further efforts at ap-
plying this concept have failed:'i30 
BeNIGN DISEASE: THE POTeNTIAL CANDIDACY POOL 
The criteria for case selection were blurred until 1980 because of a 
mortality within the first postoperative year that exceeded 60')70 IFig 
69). It was impossible to tell for certain how much case selection 
was influencing results. When this was changed with the advent of 
cyclosporine (see Fig 69), some issues of candidacy became clearer. 
In addition, with the better expectations and more general avail-
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FIG 68. 
Patient survival (life table method) after liver transplantation for benign and malignant tu-
mors that could not be treated by subtotal resection. Included are 13 patients with benign 
tumors, 54 with hepatocellular carcinoma, 18 with bile cancers, 8 with epithelioid heman-
gioendothellomas, and 12 with secondary tumors originating outside the liver. 
ability of liver transplantation, the conceptual appeal of liver trans-
plantation was so great that this procedure became the court of last 
appeal for an astonishing number of patients with lethal hepatic dis-
ease. Estimates of yearly need for liver transplantation have varied 
from as low as 15 per million population!;7 to as high as 200 per mil-
lion in an unpublished Canadian projection (Dr. Cal Stiller, personal 
communication, University of Western Ontario, London, Ontario). 
Based on these figures, and without a cap imposed by organ supply, 
between 4,000 and 50,000 liver transplantations per year could be 
needed in the United States. Since there are no practical means of 
artificial organ support analagolls to renal dialysis, the waiting list of 
recipients does not grow from year to year. 
The variability of inclusion and exclusion factors of candidacy ac-
count for the wide-ranging estimates of need. Some of the earlier low 
estimates were based on the assumption that patients with tumors 
would be excluded, that the upper age limit would be 50 years, that 
patients with Laennec's cirrhosis or othel' "sin factors" would be 
eliminated from candidacy, and that the list of applications would 
not be as extensive as has proved to be the case. Furthermore, a 
number of factors or diagnoses that precluded or strongly discour-
aged transplantation 5 or 10 years ago are no longer absolute con-
traindications, and some are no longer even questionable. 
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FIG 69. 
Patient and primary graft survival rates (life table method) after liver transplantation. One 
hundred seventy recipients were treated with azathioprine (AZA) and steroids between 
March 1963 and February 1980 compared with 1,469 recipients treated with cyclosporine 
(eYA) and steroids between March 1980 and December 1988. Follow-up is complete 
through 31 July 1989. 
Laennec's Cirrhosis 
A prime example is alcoholic cirrhosis. If there is a history of alco-
holism, it is necessary on behalf of the patient to obtain consultation 
with those who understand this disease. The objective is to ensure 
abstinence after transplantation by arranging in advance for holistic 
care. In properly selected cases, Laennec's cirrhosis may be a good 
indication (see Fig 65) .544 Recidivism with alcohol use has been less 
than 10%. 
Older Age 
An absolute upper age limit has been eliminated by demonstrating 
that recipients older than 50 years have a similar 5-year survival as 
younger adults.545 
Young Age or Small Size 
The transplantation of very small infants, even in the newborn pe-
riod of life, has become common, but the results are not as good as 
with larger children.546,547 
Portal Vein Thrombosis 
Although this was formerly a contraindication to transplanta-
tion,548,549 the newly developed vein graft techniques (see Fig 27) 
routinely allow liver replacement in recipients who have throm-
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vein grafts are jumped from the superior mesenteric vein below the 
transverse mesocolon, brought anterior to the pancreas, and used 
1'01' a portal anastomosis in the hepatic hilum. 
iHultiple Previous Operations 
Previous upper abdominal operations can complicate transplanta-
tion enormously, particularly in patients with small cirrhotic livers 
that have extensive scarring of their inflow and outflow vessels with 
obliteration of potential planes of dissection. The routine measure-
ment of liver siz;e with imaging techniques helps to identilY such 
problem cases in advance.551 The portal vein is always studied for 
patency using ultrasound and dynamic computed tomography (CT) 
scanning techniques. In uncertain cases, magnetic resonance imag-
ing is used. Splenectomy or any kind of shunting can alter the portal 
vein, and the majority of complications from transplant portal vein 
reconstruction have been in patients with such earlier operations BO 
The mesocaval and the distal splenorenal (Warren) shunts have been 
the least hannful of these procedures since they do not involve dis-
section of the portal hilum. When transplantation is performed, it is 
necessary to close the shunt to have optimal vascularization of the 
graft. 
The usual indication for a shunt operation is variceal hemorrhage, 
and the objective is to reduce portal hypertension. Should shunting 
operations ever be recommended as treatment for variceal hemor-
rhage, knowing that these procedures can jeopardiz;e the ultimate 
step of liver transplantation? Probably uncommonly, since endo-
scopic sclerosis of varices is an effective alternative.552 In some pa-
tients with child's class A (good risk) cirrhosis, a distal splendrenal 
anastomosis might be the preferred way to relieve portal hyperten-
sion. We are using this approach in a small number of highly se-
lected patients. However, it is important to emphasiz;e that the liver 
transplantation itself decompresses portal hypertension through the 
capillary bed of the normal new liver. In patients who had variceal 
bleeding and who were too sick to be considered for any operation 
other than transplantation, the 5-year survival after liver replacement 
was far superior to that reported in series of generally better-risk pa-
tients treated with shunting operation .553 The obvious limitations of 
the shunt approach to variceal bleeding has greatly reduced the fre-
quency of portal diversion procedures in Western countries. 
Other operations in the upper abdomen that were designed to 
palliate complications of liver disease can create even more serious 
problems. Examples are procedures that disconnect venous collater-
als going to lower esophageal varices and radical duct reconstruc-
tions such as those used to treat sclerosing cholangitis or biliary 
atresia (Kasai operation). 
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· As an alternative to these open operations, there has been greater 
use of interventional radiologic or endoscopic procedures, such as 
sclerosis of esophageal varices, and transhepatic duct stenting or 
dilatation. However, problem patients with previous shunts, duct 
reconstructions, or other operations in the hepatic hilum should 
not be denied transplantation foJ' this reason. Although the trans-
plant operations are made morc formidable, the results in experi-
enced hands can be almost as good as with a virgin operativc 
lield.74,554-558 
Chronic B Virus Carrier State 
It was already mentioned that there is a very high rate of recurrent 
chronic active hepatitis in these patients, for which there is no effec-
tive prevention, Because of this, some programs exclude B virus car-
riers from candidacy, However, the fact that many such patients 
have achieved benefit from transplantation makes it difficult to make 
the carrier state an absolute contraindication, 
Most efforts to treat HBsAb carriers with hyperimmune globulin 
(HBIgG) or interferon alpha have failed.4 !J7, 4!J8, 501, 503 The volume of 
commercial HBIgG that has been required to treat these patients has 
been so large as to be impractical.503 However, a human monoclonal 
antibody directed against hepatitis B viruses has been produced 
iSandoz Corporation, East Hanover, New Jersey) by fusing periphcral 
blood lymphocytes from an immune adult human male to a mousc 
X human myeloma cell lineKRR~F Thc resulting human monoclonal 
HBlgG is 50,000 times morc potent than commercially available 
HBIgG prepared from the blood of immune donors, Seven patients 
were treated with this monoclonal HBIgG beginning preoperatively 
or at the anhepatic phase of liver transplantation.54 The first recipi-
ent had reduction of surface antigen titer from very high to barely 
detectable levels, In the second patient, the surface antigen level was 
undetectable for 5 months, after which it reappeared in low titer at 
the same time as core antigen was identified in the hepatocytes of a 
hiopsy specimen that otherwise was normal. The half-life of this hu-
man monoclonal IgG was long enough to allow maintenance of an 
antibody excess with injections 2 to 4 weeks apart,54 Five patients 
have been treated with larger doses, and all are free of antigencmia 
aftel' 2 to 7 months. It remains to be seen if the recurrent discase 
pattern is appreciably altered by this kind of therapy. 
Recipients who posscss antibodies directed against the HBV sur-
face antigen have been free of hepatitis B virus following transplan-
tation. However, it has been recently recorded that patients with the 
human immunodeficiency virus (HIV) can regress from an appar-
ently immune state, as defined by anti- B virus antibodies, to an in-
fectious carrier state, apparently by reactivation of residual virus as 
their immune system fails.560 Theoretically, the same thing could oc-
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cur in a liver transplant recipient maintained on standard posttrans-
plant immunosuppression therapy. 
Non-A, Non-B Hepatitis 
Recurrence of non-A, non-B hepatitis 1+4.505 has not been common. 
The low incidence of recurrence may merely reflect the difficulty of 
establishing the diagnosis. 
Other Recurrent Diseases 
The only other unequivocal example of disease recurrence has 
been Vlrith the Budd-Chiari syndrome . Eli>. 4~D9K 561. 562 This can be pre-
vented Vlrith anticoagulation.561, 563 An initial report of recurrence of 
primary biliary cirrhosis564 in three patients has recently been 
followed by an update on these patients and evaluation of 12 more 
primary biliary cirrhosis patients who have survived for more than 
1 year. A surprising percentage565 of these long-term survivors 
showed clinical and histologic evidence of recurrent disease. Other 
groups have not been able to confirm these observations in larger 
series,447,56G-5Gi> although the antimitochondrial antibodies usually 
do not disappear after transplantation or else they reappear after 
disappearing transiently.sfili "Iii> The reason for this discrepancy is 
not readily apparent, but it appears that cyclosporine may alter dis-
ease progression and histology of primary biliary cirrhosis affecting 
either a native liver or allograft.565 Therefore, recurrences Vlrill proba-
bly not be severe or frequent enough to vitiate the value of trans-
plantation. 
A syndrome resembling sclerosing cholangitis in a liver homo-
graft has been reported,569 but the same diagnosis has been 
made after transplantation in patients who had non - biliary tract 
disease?44 There has been one report of recurrent autoimmune 
hepatitis.570 
Human Immunodeficiency Virus Carrier State 
Whether patients Vlrith antibodies to HIV should be excluded from 
candidacy is an unresolved issue. When screening tests for this dis-
ease became generally available in the spring of 1985, examples of 
HIV infections in kidney recipients were almost immediately re-
ported.s71.572 
During late 1985, a massive study of the stored sera of 1,043 kid-
ney, heart, or liver recipients treated between 1981 and 1986 was be-
gun at the University of Pittsburgh.573 Eighteen (1.7%) were found to 
be asymptomatic carriers. The liver recipients were most commonly 
affected. In about one third of the liver recipients, the HIV antibodies 
were demonstrated in their sera, which had been collected and 
stored before the transplantation. Seroconversion after liver trans-
plantation occurred in the remaining patients, for a total incidence 
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of 2.6%. The liver allograft itself was a source of infection in a minor-
ity of cases,573. 574 and most infections were attributed to blood com-
ponent therapy. Seroconversion still occurs at Pittsburgh,573 as well 
as other institutions, despite the institution of screening enzyme im-
munoassays in March 1985.575,576 
Almost certainly the presence of HIV antibodies would have pre-
cluded candidacy if the diagnosis in the foregoing cases had been 
made in advance. As it turned out, these unfortunate victims of HIV 
as well as 7 additional patients became available for long-term study 
under immunosuppression.577 Eleven of these 25 recipients were in-
fected before transplantation, although this was not known until 
later in 8. The other 14 were infected perioperatively. Ten of the 25 
recipients were infants or children. The organs transplanted were 
the liver (n = 15) and the heart or kidney (n = 5 each). After a mean 
follow-up of 2.75 years (range 0.7-6.6 years), 13 recipients are alive. 
Survival is 7 out of 15,2 out of 5, and 4 out of 5 of the liver, heart, and 
kidney recipients, respectively. The best results were in the pediatric 
group (70% survivalJ, in which only 1 of 10 patients died of AIDS. In 
contrast, AIDS caused the death of 5 of 15 adult recipients and was 
the leading cause of death. Transplantation plus immunosuppres-
sion appeared to shorten the AIDS-free time in HIV-positive patients 
compared with nontransplant hemophiliac and transfusion control 
groups. Accidental accrual of HIV-positive transplant recipients has 
slowed markedly since the systematic screening of donors, recipi-
ents, and blood products was begun in 1985. However, patients 
known to be HIV positive are still being treated. 
It is clear that many patients can have prolonged bene!it from liver 
transplantation in spite of having positive HIV test results. How to 
use this information for decision making varies from center to cen-
ter. The most commonly accepted policy in the United States is to 
screen all recipients but not to exclude transplantation solely be-
cause of a positive HTV test result. If transplantation is undertaken, 
the health care personnel must be protected from infection. It is a 
miracle that none of the surgeons who operated on our patients in 
the early 1980s without knowing the risk has (to our knowledge) 
been infected. Screening of potential donors for HIV js obligatory at 
all centers, and a 50-minute test for this purpose has been de-
scribed.578 The use of tests that identity the HIV antigens in addition 
to the antibodies579 may make donor screening more foolproof than 
it presently is. 
TIMING OF TRANSPLANTATION 
In the early days of liver transplantation, this therapeutic step 
seemed so drastic that it was used as a last resort. What was then 
defensible conservatism has become regI'Cssive today jf the patient is 
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allowed to deteriorate to the point of requiring life support systems 
before thinking of the transplant option. The rapidity of this deterio-
ration is highly variable. 
FULMINANT HEPATiC FAILURE 
The diagnosis of fulminant hepatic failure iFHF) can be made 
when there is sudden massive necrosis of a liver that previously has 
functioned normally.580-SX2 The term FHF has not been used for 
acute exacerbation of previously unrecognized chronic disease or 
for acute Wilson's disease. It was rarely treated with liver transplan-
tation before 1982.67 The results with transplantation has not been 
good enough to justiiY this drastic step for a disease syndrome from 
which recovery might occur in 5% to 20% of cases:~u[F-RuO Since then, 
FHF has been accepted as an emergency indication for transplanta-
tion in almost every liver transplant program worldwide. In several 
large sories,58:1-591 the predominant diagnoses have been non-A, 
non-B hepatitis, B virus hepatitis, and toxic hepatitis from a variety 
of agents. Mushroom poisoning has been a much publicized toxic 
etiology.592 In our hands, the original diagnosis has strongly influ-
enced the outcome (Fig 70). The best results have been with B virus 
hepatitis. 
A decision to proceed with liver replacement often must be made 
in a few hours. The systematic coUation of multiple parameters can 
help distinguish patients who have a good chance of recovelY from 
those who will die without transplantation.593. 5!J4 The etiology of the 
FHF may be an important prognostic determinant.594 Premonitors of 
imminent death include relentless progression over a 7- to 14-day 
period, grade 3 or 4 encephalopathy, severe coagulopathy, rapid 
shrinkage of the liver as documented with imaging techniques, met-
abolic acidosis, cardiovascular instability, and sepsis.585.586 By the 
time there is grade 4 encephalopathy and ventilator dependence, it 
usually is too late. 
H transplantation is performed before these grave findings, some 
livers with reversible lesions may be replaced unnecessarily. A liver 
biopsy aftor correction of the coagulopathy may provide decisive in-
formation. if clotting cannot be corrected well enough to permit a 
closed needle biopsy, the patient can be explored with a new liver in 
hand with the option of aborting the operation if the open biopsy 
looks favorable histopathologically. In spite of the pitfalls associated 
with liver replacement for FHF, current posttransplant survival rates 
of 55% to 75% 583-5fl1 compare favorably with the most optimistic 
projections of 20% for medical management alone. The results make 
it certain that these efforts will continue. The perioperative mortality 
frequently has been due to brain stem herniation during or just after 
transplantation, sometimes in spite of continuous monitoring of in-
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Patient survival (life table method) after liver transplantation in adults and children for ful-
minant hepatic failure. Included are 9 cases of drug-related liver failure, 13 cases of acute 
B virus hepatitis, 31 cases of acute non-A non-B hepatitis, 13 cases of acute hepatitis A, 
and 4 cases of fulminant hepatic failure of unknown etiology, 
tracranial pressure. Early referral to li\-er transplant centers, ex-
tremely aggressive evaluation plus medical treatment, and an early 
decision for surgical exploration with immediate transplantation as 
an option will be necessary to improve results. 
It will be unfortunate if the availability of transplantation causes 
the therapeutic pendulum to swing too far toward liver replacement. 
In the hepatology unit at King's College. London, the admission of 
patients with FIlF to an intensive care unit, the continuolls monitor-
ing of intracranial pressure, and attention to multiple details has re-
sulted in greatly improved survival (more than 50%) of patients 
whose survival expectation in the past would have been less than 
20% :~lg4 They emphasize the value of IV mannitol treatment as a 
means of brain shrinkage and hypoventilation on respirator control 
to encourage cerebrovascular vasodilitation by keeping the Pcoz ele-
vated.5D4 
Similarly, Levy Sinclair and associates of Toronto have reported 
the astonishing recovelY of patients (10 or 171 \Nith FHF.5lJ5 Some of 
their patients had liver biopsies in which it was difficult to find a 
single living hepatocyte. They ascribed their success to prostaglan-
din E, namely, Prostin, a synthetic prostaglandin that can be given 
intrm'enously or orally. In their opinion. an important, and possibly 
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the principal, value of Prostin was to preserve the integrity of the he-
patic microvasculature and thus to ensure a viable scaffold on which 
regeneration could proceed. 
END-ST/1GE CHRONIC IJISEA,)E 
Ideany, a candidate for liver replacement should have an unequiv-
ocal need for transplantation but still be well enough to participate 
in the complex process of recovery. A decision to go forward re-
quires input from the primary physician, who may see gradually 
evolving and often appalling social and vocational invalidism that 
may not be evident at first examination. The disability may be re-
flected in the loss of intellectual capacity with encephalopathic de-
mentia, ti'equent hospitalizations for other complications of liver fail-
ure, inability to function in a domestic environment, and arrest of 
growth and development in infants and children. These issues of 
quality of life loom large in most patients long before the truly termi-
nal events of chronic hepatic failure. Formulas for candidacy based 
on liver function tests have not been helpful because the abnormal-
ities in these tests are so variable from disease to disease or even 
within the same disease. Patients with cholestatic disorders (e.g., bil-
iary atresia and primary biliary cirrhosis I usually become deeply 
jaundiced "vith good preservation of hepatic synthetic functions for 
a long time,520 525,557 whereas patients with hepatocellular disease 
may not be jaundiced in spite of the most profound depressions in 
albumin and prothrombin synthesis,548 
The liability of procrastinating too long before making a decision 
for transplantation has yet to be defined, In one study in which 12% 
of candidates died "while waiting," most of the lost patients had ar-
rived at the transplant hospital on ventilators and had GI bleeding, 
coagulopathies, the hepatorenal syndrome, aspiration pneumonitis, 
subacute bacterial peritonitis, or other end-stage complicationsIR~FS 
In another center, the mortality in patients considered too well to be 
placed on the active waiting list was greater than for those admitted 
to candidacy.597 When the mistake of underestimating disease sever-
ity with the supervention of a catastrophic complication is made, re-
suscitation is sometimes successful. However, the outlook after sub-
sequent transplantation is demonstrably degraded,598,599 notwith-
standing observations in a small group of pediatric liver recipients 
that disease severity did not seem to influence posttransplantation 
prognosis.GOO 
The most precise studies of disease staging vs. posttransplantation 
outcome have been in adult patients with primary biliary cirrho-
sis.GOI, 602 In the most recent of these investigations,li01 disease sever-
ity was defined with a formula in which age, serum bilirubin level, 
serum albumin level, prothrombin time, and edema severity accu-
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Comparison of the projected survival in patients with primary biliary cirrhosis when treated 
with transplantation (Kaplan-Meier) VS. the expected outcome with all alternative forms of 
treatment (Mayo model). (From Markus BH, Dickson ER, Grambsch PM, et al: N Eng! J 
Med 1989; 320:1709-1713. Used by permission.) 
rately predicted life expectancy without transplantation.Go:l The 
overall survival in transplant recipients was greatly improved relative 
to these predictions (Fig 71). However, the patients who were still in 
reasonable condition had a low perioperative mortality and a 2-year 
survival of 80%; those with the most serious deterioration had a high 
perioperative mortality and a 2-year survival of only 55% (Fig 72).601 
The consensus in most centers is that transplantation should be 
considered at an earlier time before the stage of catastrophic com-
plications is reached.604 
Recently, an increasing number of patients with normal liver func-
tion and nonmalignant hepatic masses have had orthotopic trans-
plantation for polycystic disease,217,219 cystic hygroma,605 and ade-
nomatosis. The siz.e of those lesions and the consequent disability 
and life-threatening complications of the mass lesions were the indi-
cations for operation. The largest of the excised livers weighed 
16.5 kg.GD5 
THE QUESTION OF RET1'.ANSPLANl'ATiON 
Before the advent of cyclosporine, retransplantation was a rare 
event. Consequently, the graft and patient survival were almost syn-
onymous (see Fig 69). Almost immediately after the introduction of 
cyclosporine, attempts at retransplantation began to be made and 
with enough success to warrant further such effor1s.67 Now the pa-
tient survival curves began to be 10% to 15% above the graft survival 
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before referral and treatment of patients with this disease. (From Markus BH, Dickson ER, 
Grambsch PM. et al: N Eng/ J Med 1989; 320:1709-1713. Used by permission.) 
curves (sec Fig 69). In the United States at the present time, approx-
imately one fifth of all liver grafts are used for retransplantation. The 
need for retransplantation is often extremely urgent, and many pa-
tients have a clinical syndrome comparable with or worse than ful-
minant hepatic failure. 
The success rate with retransplantation is only about one half of 
that if a primary graft succeeds (Fig 73). The chances of 5-year sur-
vival with a "take" of the first graft is about 75% (see Fig 73), almost 
twice as good as the expectation if two or more grafts are needed. 
This low success rate with retransplantation has caused ethicists to 
question the probity of continuing these efforts. Yet, the salvage of so 
many patients whose first grafts have failed seems more than ade-
quate justification for what has been done. 
If the option of retransplantation was foreclosed, it would have a 
chilling effect on donor acceptance since the philosophy of one 
chance only would discourage the transplantation of grafts with 
more than minimal preservation times and would greatly tighten the 
requirements for donor consideration. No liver transplant surgeon of 
whom we are aware would countenance the concept of patient 
abandonment implicit in a policy that precludes or even discour-
ages retransplantation in a patient who is potentially salvageable. 
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Survival of patients who required only one graft (1,125 cases) IS significantly better (p < 
0.001) than for patients requiring two transplants (268 cases) or three or more transplants 
(76 patients). 
INBORN ERRORS OF METABOLISM: A PANDORA'S BOX 
Patients \vith liver-based inborn errors of metabolism can be 
treated by providing a phenotypically normal liverz37, 464, 606-ti3D It 
was recognized long ago and confirmed repeatedly since that the 
a-globulins, haptoglobin,237.464 and group-specific component,464 as 
well as other products of hepatic synthesis,li40-645 permanently re-
tain the original metabolic specificity of the donor after transplanta-
tion. These observations made it virtually certain that liver trans-
plantation would become a decisive way to treat the inborn errors of 
metabolism that resulted partly or completely from deficiencies of 
specific liver enzymes or from abnormal products of hepatic synthe-
sis. This expectation has been fulfilled in many patients for whom 
follow-ups of as long as 18 years after transplantation are available 
(Table 12). With other disorders in which the pathogenesis was not 
well understood, the transplantation itself became a powerful re-
search tool by showing the extent of correction and by elucidating 
the mechanisms by which correction was accomplished (see Ta-
ble 12l. In one patient, the opposite of a therapeutic correction was 
achieved in that a coagulation defect present in the donor was con-
ferred on the recipient.G46 
In the majority of these recipients, the inborn error had itself been 
responsible for damage to the liver, and a conventional indication of 
liver failure or the development of malignant tumors prompted the 
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liver replacement. In these cases, the correction of the metabolic er-
ror was incidental. However, an increasing number of transplanta-
tions have been carried out solely for the purpose of correcting the 
inborn error, and in many of these latter patients Isee Table 121, the 
excised liver has been anatomically normal. 
Many inborn errors not correctable by liver transplantation can be 
effectively treated with allogeneic bone marrow engraftment.6--17 De-
termining which kind of transplantation vvill be effective is crucial 
whenever somatic metabolic engineering is considered. The guide-
lines for decision making have become increasingly clear.5--1.6--17 
TRANSPLANTATION OF MULTIPLE ORGANS 
The increasing boldness with which hepatic transplantation has 
been applied is evident from the many reports of transplantation of 
the liver plus kidneYl7. 219. 6--18-651 and less frequently used combina-
tions of the liver plus pancreas,281 liver plus heart,632-635.652 and 
liver plus heart and lung.653 In these cases, the liver transplantation 
and transplantation of the other organ have been done in disconti-
nuity so that two standard procedures were performed in the same 
individual. 
A different concept has been the inclusion of the liver in visceral 
organ clusters. The most complex operation of this kind has been of 
.. 
FIG 74. 
Left, delineation in embryonal life of that region of the GI tract (dark shaded) that was re-
sected in the organ cluster operation (E = esophagus; LB = lung bud; L = liver; P = pan-
creas). Right, the adult organs deriving from the shaded primitive analogue. (From Starzl 
TE, Todo S, Tzakis A: Ann Surg 1989; 210:374-386. Used by permission.) 
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FIG 75. 
The CT scan (top) 01 patient whose upper abdomen was Iilled with spindle cell sarcoma at 
the time of operation. The tumor-laden liver is the structure to the left of the operating room 
photograph (bottom). Most 01 the right half 01 the diaphragm was removed with the spec-
imen. The transverse colon is marked with white arrows. The margins were free of tumor , 
and none 01 the 38 lymph nodes studied had metastases. (From Starzl TE, Todo S, Tzakis 
A Ann Surg 1989; 210:374-386. Used by permission.) 
the liver and pancreas plus the entire GI tract in two children with 
the short-gut syndrome and secondary liver failure that developed 
during parenteral hyperalimentation.654. 6 .'>5 One of these grafts (Fig 
74) provided function of all of the organs for more than 6 months 
before the recipient died of complications of lymphoproliferative tu-
mors in the liverG54 With an organ mass of this size, the possibility of 
carrier lymphoid tissue causing GVH disease was feared. In the long-
est surviving patient. donor pretreatment with OKT3 may have re-
duced this threat,654 as has been demonstrated to occur with anti-
lymphocyte serum in rats.bSG 
f\ less drastic version of multivisceral transplantation is the use of 
an organ cluster in which the pancreas, duodenum, and part of the 
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FIG 76. 
Removal of organ cluster graft from donor. The specimen is initially cooled with an aortic 
infusion of UW solution after crossclamping the proximal abdominal aorta. Once the spec-
imen has been removed with a Carrel patch containing the origin of the cellae axis (CA) 
and superior mesenteric artery (SMA), the liver IS secondarily perfused on the back table 
with UW solution (insert) through the superior mesenteric vein (SMV). (From Starzl TE, 
Todo S, Tzakis A: Ann Surg 1989; 210:374-386. Used by permission,) 
proximal jejunum have been included with the liver.5 ' 1,657 These 
clusters have been used to replace upper abdominal organs that 
were removed (see Fig 74) in treating sarcomas and carcinoid tumors 
of the pancreas or duodenum with liver metastases IFig 75), bile 
duct carcinomas \-'lith liver metastases, and a hepatoma that had in-
vaded the duodenum and colon. fi57 The organs removed from the 
recipient in continuity have included the liver, stomach, pancreas, 
spleen, duodenum, proximal jejunum, and ascending plus trans-
verse colon (see Fig 74). The organs transplanted are shown in Fig-
ure 76. The completed recipient operation is shown in Figure 77. 
Of 15 such patients, 9 are alive after 6 to 14 months, 8 without ev-
idence of recurrent tumor. The ninth survivor may have stable pul-
monmy metastases. The majority of the sUIvivors have been rehabil-
itated. This experience has illustrated how major components of the 
GI tract can be transplanted and has demonstrated how the use of 
organ clusters can allow extirpative procedures of a magnitude not 
previously imaginable. 
The major limitations of the cluster operation have been the diffi-
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FIG 77. 
Completed reconstruction in the recipient. (From Starzl TE, Todo S, Tzakis A: Ann Surg 
1989; 210374-386. Used by permission.) 
culty of finding appropriate organ donors, the difficulty of the oper-
ation, and the complexity of postoperative care. Considering the fact 
that of the organs being replaced, only the liver is indispensable, an 
alternative was developed in which the same resection was per-
formed but only the liver was transplanted (Fig 78). Fifteen such pa-
tients have been so treated, but the follow-ups are too short to merit 
comment. This variation of the original cluster procedure has been 
developed as a more pragmatic operation but at the expense of ren-
dering the patient apancreatic. Malabsorption has been a serious 
clinical problem thus far, and thus it may influence cyclosporine 
doses. The day-to-day treatment of diabetes mellitus has not been 
difficult. If management of the iatrogenic diabetes mellitus proves 
difficult, pancreas transplantation at a more favo!'able moment re-
mains an option. 
QUALITY OF LIFE 
Even in the early days of liver transplantation, the physical and 
emotional decay caused by chronic liver disease could be stopped 
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FIG 78. 
This is an alternative to the reconstruction after an upper abdominal exenteration in which 
only the liver is replaced. This operation leaves the patient diabetic, but of 15 patients 
treated in this way, 13 are alive with follow-ups of several weeks to as long as 6 months. 
(From Tzakis A, Todo S, Starzl TE: Transplant Proc February 1990 [ill press]. Used by per-
mission.) 
and reversed in many of the recipients who survived chronically. 
The most powerful determinants of their quality of life were the liver 
function profile at the i-year convalescent mark and the quantity of 
steroids needed to maintain this function.658 The adverse steroid 
factor in the quality of posHl'ansplant life has been reduced since 
the introduction of cyclosporine. Several studies have shown the re-
markable restoration of physical and emotional well-being that can 
be expected in infants and children,l;38-G60 including resumption of 
growth or even catch-up growth.(jol 
Similarly, a recent group of adult liver transplant recipients stud-
ied objectively before and again 2 years after operation demon-
strated broad improvement in social interaction, home management, 
alertness, the utilization of recreation and leisure time, and overall 
psychosocial functioning.662 A number of other findings were ob-
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tained from these investigations. First, the severity of stress experi-
enced by the patient and the spouse after transplantation correlated 
significantly with the ease of recovery. More than 90% of the recipi-
ents who had a single transplantation state that they have no prob-
lems or only minor health problems 2 years after transplantation. 
More than 85% have returned to work and state that they are able to 
perform their jobs well. In contrast, the smaller number who re-
quired more than one transplant had a much poorer outcome, with 
only 43% being able to work because of one or more disabilities. 
The follow-up of patients treated in the cyclosporine era dates 
back to only 1980. However, a bellwether group of survivors remains 
from an original series of 170 patients treated from 1963 to 1979.67,663 
Twenty-eight of these recipients are still living after 10 to 19 years. 
These represented exactly one half of the survivors at 1 year. Only 
two patients who were alive at 5 years died subsequently. One of the 
late deaths was caused by chronic rejection 12.5 years after retrans-
plantation. The other death was from a lymphoma after 13.5 years. 
Rehabilitation has been complete in the long survivors.663 
THE OPTION OF AUXILIARY TRANSPLANTATION 
With the auxiliary operation, as originally described in unmodified 
dogs,t the extra liver was placed in the right paravertebral gutter, 
rearterialized from convenient adjacent vessels, and provided with a 
portal venous inflow with systemic blood from the recipient iliac 
vein or lower vena cava. The graft outflow was drained into the re-
cipient inferior vena cava. It was observed that auxiliary grafts were 
much more severely damaged than were orthotopically placed liv-
ers, primarily because of rapid hepatocyte atrophy.664 These adverse 
effects could be prevented by diverting splanchnic venous flow 
through the auxiliary liver and away from the recipient's own liv-
er,665 suggesting that the splanchnic venous blood contained spe-
cific liver-supporting factors. The most important of these so-called 
portal hepatrophic substances was proved to be insulin.325,666 
The condition of providing a splanchnic venous inflow to the graft 
has been met in almost all of the subsequent clinical trials, which by 
1978 numbered more than 50 (Fig 79).667 Auxiliary liver transplanta-
tion with unquestionable prolongation of life was first achieved at 
the New York Memorial Hospital on December 13, 1972.668 The re-
cipient, who had biliary atresia, still is alive with a follow-up of more 
than 16 years.669 In 1980, Houssin and associates in Paris reported a 
29-month survival of an adult who was given an extra liver.67o This 
patient was HBsAg-positive and died 8 years following transplanta-
tion from a hepatocellular carcinoma in his host liver (H. Bismuth, 
personal communication, January 1989). 
With the increased success of orthotopic liver transplantation, in-
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FIG 79. 
Celiac axis 
graft 
This is the kind of auxiliary liver transplantation that has permitted several long-term suc-
cesses. Note that the graft receives a portal flow from the splanchnic venous system 
(S.M. V.) and is drained into the inferior vena cava (I. V.C.). The principles of this operation 
were originally worked out by Marcrlioro and colleagues. 18 (From Starzl TE [with the assIs-
tance of Putnam CW): Experience in Hepatic Transplantation. Philadelphia. WB Saunders 
Co, 1969. Used by permission.) 
terest in auxiliary transplantation waned. Very few further effol,ts 
were reported in the last decade.6TI The resulting pessimism has 
been lightened by a recent report of the transplantation of whole liv-
ers or liver fragments to the right paravertebral gutter of six adult re-
cipients using essentially the same operation as that tried in earlier 
times.672 At the time of reporting with follow-ups of 5 to 23 months, 
all six recipients were alive. Cautious further trials undoubtedly will 
be forthcoming. 
PRACTICAL ,-,IMITATIONS 
ORGAN SUPPLY 
Organ supply increasingly will influence candidacy criteria. How-
ever, discussions about rationing transplant services for this reason 
are premature since the balance between the need and supply of Iiv-
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ers has not been determined. In the United States, the yearly rate of 
liver transplantations has reached approximately 1,600,673 averaging 
147 per month between July and December 1988 (Dr. William 
Vaughn, United Network of Organ Sharing, personal communica-
tion, 1989). The annual European total is approaching this figure.674 
Policies about organ donation will have to be reexamined if sub-
stantial further growth is to occur. Probably, many potential liver do-
nors are being rejected for inappropriate reasons. The arbitrary up-
per age limit for liver donors observed by most programs675 cannot 
be justified since the liver is the only organ that does not undergo 
senescence.676 Atherosclerosis of its arterial supply usually is not 
found beyond the origin of the celiac axis.676 A limited experience 
with livers from donors older than 50 years has been encouraging.677 
Other potential donors of all ages often are excluded because of 
poor blood gases, a need for inotropic or vasopressor drugs, minor 
abnormalities of liver function test results, or the existence of other 
diseases such as diabetes mellitus.675 The results with such donors 
both in the United States 161, 162 and Europe163 have been as good as 
with so-called perfect donors. The use of better preservation tech-
niques51- 53 that allow safe storage of liver grafts for 1 day instead of 
the previous 6 or 8 hours should reduce organ wastage, since with 
this extra time, countrywide and worldwide networks of organ shar-
ing can be set up. 
ECONOMIC FACTORS 
The ability to pay for liver transplantation has had a profound in-
fluence on candidacy. Ironically, the feasibility first and then the 
practicality of liver transplantation were established without consid-
ering how to finance this revolutionary form of therapy. In 1983, a 
planning commission for the state of Massachusetts estimated the 
average cost of liver transplantation in the first year would be 
$238,000,678 although the actual costs were only one third this high 
in a large program already in existence.114 It is clear that astronomi-
cal bills can be generated if patients are too disabled by the time of 
transplantation, if the first liver graft does not function well, and if 
serious complications develop, including the need for retransplanta-
tion.114 
Because of their fear of runaway expenses, many health insurance 
carriers and government agencies have avoided financial responsi-
bility to their constituents by classifYing liver transplantation as "ex-
perimental,,679 in spite of the Consensus Development Conference 
conclusion to the contrary. The response to cost-conscious funding 
agencies is that liver transplantation can eliminate repeated and ex-
pensive hospitalization of patients who are slowly dying with 
chronic hepatic disease.68o-682 Such considerations were part of a 
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bitter controversv in Australia683, 684 about the establishment of what 
eventually proved to be two outstanding programs.G8S , G8G 
SO far, liver transplantation in the United States has been paid for 
by a heterogenous system of private health care insurance programs, 
government agencies, and public or private fund-raising activities. 
One highly visible consequence has been the recurrent spectacle of 
a family or patient pleading on television or through other media few 
economic support or for an organ. All the while, statistics that shmv 
gross underparticipation in this new kind of health care by blacks 
and presumably other disadvantaged groups have been accruing(,87 
Development of a system that allows all citizens equal and reason-
able access to this kind of treatment without the extraordinary ex-
penses of past programs such as the federally financed End Stage 
Renal Disease program may require new and creative administrative 
approaches. 
REFERENCES' 
470. Fulginiti VA, Schribner p, Groth CG, et al: Infections in recipients of liver 
homografts. N Engl J Med 1968; 279:619-626. 
47l. Schroter GPJ, Hoelscher M, Putnam CW, et al: Infections complicating or-
thotopic liver transplantation: A study emphasizing graft-related septicE~­
mia.Arch Surg 1976; 111:1337-1;)47. 
472. Schroter GPJ, Hoelschel' 1\1, Putnam CW, et al: Fungus infections after liver 
transplantation. Arch Surg f~gTT; 186:115-122. 
473. Colonna JO II, Winston DJ, Brill JE, et al: Infectious complications in liver 
transplantation. Arch Surg 1~FUU; 123:360- 364. 
474. Kusne S, Dummer JS, Singh 1\:, et al: Fungal infections after liver transplan-
tation. Transplant Proc 1988; 20lsuppl 1):650-651. 
475. Korvick JA, Marsh W, Starzl TE, et al: Pseudomonas acruginosa bacteremia 
in patients undergoing liver transplantation: An emerging problem. Surgery 
(in press). 
476. Brettschneider L, Tong JL, Boose DS, et al: Specific bacteriologic problems 
after orthotopic liver transplantation in dogs and pigs. Arch Surg 1968; 
97:313- 322. 
477. Guiot HFL, van del' Meer JWM, van Furth R: Selective antimicrobial modu-
lation of human microbial flora: Infection prevention in patients with de-
creased host defense mechanisms by selective elimination of potentially 
pathogenic bacteria. J Infect Dis 1981; 14:1:644-654. 
478. Koneru B, ScantlebUlY V, Makowka ]" et al: Infections in pediatric liver re-
cipients treated for acute rejection. Transplant Proc 1989; 21:2251-2252. 
4nJ. Mai M, Nery J, Sutker B, et al: DHPG I.Gancyclovir! improves suIVival in CMV 
pneumonia. Transplant ['roc 1989; 21:2263-2265. 
480. Jacobs F, Van de Stadt J, nourgeois N, et al: Severe infections after cady 
liver transplantation. Transplant Proc f~gU9; 21:2271-2273. 
481. Saliba F, Arulnaden JL, Gugcnheim .I, et al: CMV hyperimmune globulin 
prophylaxis after liver transplantation: A pmspective randomized con-
trolled study. Transplant Proc 1989; 21:2260-2262. 
*References 1 through 180 appear in Part I, references 181 through 469 appear 
in Part II, and references 470 through 687 appear in Part III. 
.230 Curr Prabl Surg, April 1990 
482. Harbison MA, De Girolami Pc' Jenkins RL, et al: Ganciclovir therapy of se-
vere cytomegalovirus infections in solid-organ transplant recipients. Trans-
plantation 1988; 46:82-88. 
483. Erice A, Sunwen C, Biron KK, et al: Progressive disease due to Gancyclovir-
resistant cytomegalovirus in immunocompromised patients. Med Intelli-
gence 1989; 320:289-291. 
484. Demetris AJ: Pathology of liver transplantation, in Popper Ii, Schaffner F 
(eds): Progress in Liver Disease 1989, vol 9. 
485. Carter RL, Penman HG: Infectious Mononucleosis. Boston, Blackwell Scien-
tific Publications, 1969. 
486. Purtilo DT: Malignant lymphoproliferative disease induced by Epstein-Barr 
virus in immunodeficient patients including X-linked cytogenetic and fa-
milial syndromes. Can Genet Cytogenet 1982; 4:251-268. 
487. Ziegler JL, Beckstead JA, Volberding PA, et al: Non-Hodgskin's lymphoma in 
90 homosexual men. Relation to generalized lymphadenopathy and the ac-
quired immunodeficicncy syndrome. N Engl J Med 1984; 311:565-570. 
488. Starzl TE, Nalesnik MA, Porter KA, et al: Reversibility of lymphomas and 
lymphoproliferative lesions development under cyclosporin-steroid ther-
apy. Lancel 1984; 1:583-587. 
489. Nalesnik MA, JaffE R, Starzl TE, ct al: The pathology of post-tt'ansplant lym-
phopmliferative disorders (PTLD's) occurring in the setting of cyclospol'in 
A- prednisone immunosuppression. Am J Patl1011988; 133:173-19Z. 
490. Makowka L, Nalesnik MA, Stieber A, et al: Control of post-transplant lym-
phoproliferative disorders and Kaposi's sarcoma hy modulation of immu-
nosuppression, in Good RA (cd): The Nature, Cellular and Biochemical 
Bases, and Management of Immunodeficiency. New York, FK Schattauer 
Verlag, 1987, pp 567-618. 
491. Nalesnik MA, Makowka L, Starzl TE: The diagnosis and treatment of post-
transplant lymphoproliferative disorders. Curl' Probl Surg 1988; Z5:371-472. 
492. Breining MK, Zitclli B, Starzl TE, et al: Epstein-Barr virus, cytomegalovit·us 
and other virus infections in children aftcr transplantation. J Infect Dis 
1987; 156:273-Z79. 
493. Hanto DW, Frizzera G, Kazimiera J, et al: Epstein-Bal'l' virus inducted B-cell 
lymphoma after renal transplantation, acyclovir therapy and transition 
from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1 ~gUO; 
306:913- 918. 
494. Schnitzer B: Reactive lymphoid hyperplasia, in Jaffe ES led): Surgical Pa-
thology of the Lymph Nodes and Related Organs. Philadelphia, WB Saunders 
Co, 1985, pp ZZ-56. 
4~gRK Strong yVB: Adenovirus isolations from patients with infectio"s hepatitis. 
CDC Hepatitis Surveillance Report No 22, Centers for Disease ControL At-
lanta, 1965, p 17. 
496. Curman JL, Putnam CW, Iwatsuki S, et al: Liver allograft. Its use in chronic 
active hepatitis with macronodular cirrhosis, hepatitis B surface antigen. 
Arch Surg 1979; 114:75-78. 
4~gTK Demetris AJ, Jaffe R, Sheahan DG, et al: Recurrent hepatitis B in liver al-
lograft recipients. Differentiation between viral hepatilis B and rejection. 
Am J Patho11986; 125:161-172. 
498. Portmann B, O'Grady J, Williams R: Disease recurrence following orthoto-
pic livm' transplantation. Transplant Proc 1~gUS; 18(suppl 4):136-143. 
499. Pichlmayr R, Ringe B, Lauchart YV, et al: Liver transplantation. Transplant 
Proc 1987; 19:103-112. 
500. Colledan M, Gislon M, Doglia M, et al: Liver transplantation in patients 
Curl' Probl Surg, April 1990 231 
with B viral hepatitis and delta infection. Transplant Proc 1987; 19:4073-
4076. 
501. Rizzetto M, Macagno S, Chiaberge E, et al: Liver transplantation in hepatitis 
delta virus disease. Lancet 1987; 2:469-471. 
502. Johnson PJ, Wansbrough-Jones MH, POl'tmann B, et al: Familial HGsAG-
positive hepatoma: Treatnwnt vvith orthotopic liver transplantation and 
specific immunoglobulin. HI' tv/ed J (Clin Res) 1978; 1:216. 
5(1:3. Lauchart W, Muller R, Pichlmayr R: Long-teI'm immunoprophylaxis of hep-
atitis B virus reinfection in recipients of human liver allografts. Transplant 
Proc 1987; 19:4051-4053. 
504. Kuo G, Choo QL, Alter HJ, et al: An assay fOl' circulating antibodies to a ma-
jor etiologic virus of human non-A, non-B hepatitis. Science 1989: 
244 :362 - 364. 
505. Wall WJ, Duff JH, Ghent CN, et al: Liver transplantation: The initial experi-
ence of a Canadian Centre. Can J Surg 1985; 28:286-289. 
506. Ajlouni K, Doeblin TD: The syndrome of hepatitis and aplastic anemia. BrJ 
Haematol1974; 27:345-355. 
507. Zeldis JB, Dienstag JS, Gale RP: Aplastic anemia associated with non-A non-
B hepatitis. Am J Med 1983; 74:64-68. 
508. Stock PG, Steiner M, Freese D, et al: Hepatitis associated aplastic anemia 
after liver transplantation. Transplantation 1987; 4P:R9R-R~gTK 
509. Tzakis AG, Arditi M, Whitington PF, et al: Aplastic anemia complicating or-
thotopic liver transplantation for non-A, non-B hepatitis. N Engl J Med 
1988; 319:393-396. 
510. Letkowitch JH: Bile ductular cholestasis: An ominous histopathologic sign 
related to sepsis and cholangitis lenta. Hum Patho11982; 13:19-24. 
511. Opelz G: Effect ofHLA matching in 10,000 cyclosporine-treated cadaver kid-
ney transplants. Transplant Proc 1~FUT; 19:641. 
512. Yacoub M, Festenstein P, Doyle A: The inHuence of HLA matching in car-
diac allograft recipients receiving cyclospmine and azathioprine. Trans-
plant Proc 1987; 19:2487-2489. 
513. Markus BH, Duquesnoy RJ, Gordon RD, et a1: Histocompatibility and liver 
transplant outcome. Does HLA exert a dualistic effect? Transplantation 
1988; 46:372-377. 
514. Iwatsuki S, Starzl TE, Todo S, et al: Experience in 1,000 liver transplants un-
der cyclosporine-steroid therapy: A survival report. Transplant Proc 1988; 
20(suppl II :498-504. 
515. O'Grady JG, Williams R: Results, disease recurrence and rehabilitation in 
liver transplantation, in CaIne R (edl: The Cambridge-King's College Hospi-
tal Experience, ed 2. New York, Grune &, Stratton, 1987, p 485. 
S16. Starzl TE, Demetris Al, Van Thiel D: Medical progress: Liver transplanta-
tion (Part I). N Engl J Med 1989; 321:1014-1022. Part II, 1989; 321:1092-1099. 
517. Adler M, Gavaler JS, Duquesnoy R, et al: The relationship between the diag-
nosis, preoperative evaluation, and prognosis after orthotopic liver trans-
plantation. Ann Surg 1988; 208:196-202. 
S18. Busuttil RW, Colonna JO, Hiatt JR, et al: The first 100 liver transplants at 
UCLA. Ann Surg 1987; 206:387-402. 
519. Samuel D, Benhamou JP, Bismuth E, et al: Criteria of selection for liver 
transplantation. Transplant Proc 1987; 19:2383-2386. 
520. Iwatsuki S, Shaw BW Jr, Starzl TE: Liver transplantation for biliary atresia. 
World J Surg 1984; 8:S1-56. 
521. Zitelli BJ, Malatack JJ, Gartner JC Jr, et al: Evaluation of the pediatric pa-
tient for liver transplantation. Pediatrics 1986; 78:SS9-565. 
23.2 Curl' Prabl Surg, April 1990 
522. Millis JM, Brems JJ, Hiatt JR, et al: Orthotopic liver transplantation in biliary 
atresia. Evolution and management. Arch 511rg 1988; 123:1237-1239. 
523. Burcklski M. Ringe B, Bodeck B. et al: Indications and results of liver tI'ans-
plantation in childhood. Monatsschr Kinderheilkd 1988; 136:317-322. 
524. Paradis KJ, Freese DK, Sharp HL: A pediatric perspective on liver trans-
plantation. Pediatr Clin North Am 1988; 35:409-433. 
525. Esquivel CO, Marsh JW, Van Thiel DH: Liver transplantation for chronic 
cholestatic liver disease in adults and children. Gastroenterol Ciin North 
Am 1988; 17:145-155. 
526. Esquivel CO, Iwatsuki S, Gordon RD, et al: Indications for pediatric liver 
transplantation. J Pediatr 1987; 3:1039-1045. 
527. Iwatsuki S, Gordon RD, Shaw BW Jr, et al: Role of liver transplantation in 
cancer therapy. Ann 511rg 1985; 202:401-407. 
528. Stone MG, Klintmalm GB, Polter D, et al: Neo-adjuvant chemotherapy in 
liver transplantation for hepatocellular carcinoma. Transplantation 1989; 
48:344-347. 
529. Huber C Niederwieser D, Schonitzer D, et al: Liver transplantation followed 
by high-dose cyclosphosphamide, total-body irradiation, and autologous 
bone marrow transplantation for treatment of metastatic breast cancer. A 
case report. Transplantation 1984; 37:311-312. 
530. Margreiter R: Indications for liver transplantation for primary and second-
ary liver tumors. Transplant Proc 1986; 181suppl 31:74-77. 
531. Koneru B, Casavilla A, Bowman J, et al: Liver transplantation for malignant 
tumors. Gastroenterol Clin NorthAm 1988; 17:177-193. 
532. Friend PJ, Lim S, Smith M, et al: Liver transplantation in the Cambridge/ 
King's College Hospital Series-the first 400 patients. Transplant Proc z~gU9; 
21:2397-2398. 
533. Wall WJ: Liver transplantation: Current concepts. Can Med Assoc J 1988; 
139:21-28. 
534. O'Grady JG, Williams R: Liver transplantation for malignant disease. Results 
in 93 consecutive patients. Ann 511rg 1988; 207:373-379. 
535. Makowka L, Tzakis AG, Mazzaferro V, et al: Liver transplantation fol' meta-
static endocl'ine tumol's of the intestine and pancreas. 511rg Gynecol Obslet 
1989; 168:107-111. 
536. Pichlmayr R, Ringe B, Wittekind C, et al: Liver grafting for malignant tu-
mors. Transplant Proc 1989; 21:2403-2405. 
S37. Craig JR, Peters RL, Edmondson HA, et al: Fibrolamellar can;inoma of the 
liveI'; a tumor of adolescents and young adults with distinctive clinico-
pathologic featul'es. Cancer 1980; 46:372-379. 
538. Berman MM, Libby NP, Foster JH: Hepatocellular carcinoma; polygonal cell 
type with fibrous stroma-an atypical variant with a favol'able prognosis. 
Cancer 1980; 46:1448-1455. 
539. Starzl TE, Iwatsuki S, Shaw BW Jr, et al: Treatment of fibrolamellar he-
patoma with partial or total hepatectomy and transplantation of the liver. 
5urg Gynecol Obstet 1986; 162:145-148. 
540. Weiss SW, Enzinger FM: Epithelioid hemangioendotheliomas. A vascular 
tumor often mistaken for a carcinoma. Cancer 1982; 50:970-981. 
541. Marino IR, Todo S, Tzakis AG, et al: Treatment of hepatic epithelioid he-
mangioendothelioma with liver transplantation. Cancer 1988; 62:2079-2084. 
542. Mulbacher F, Piza F: Orthotopic liver transplantation for secondary malig-
nancies of the liver. Transplant Proc 1987; 19:2396-2398. 
543. Colonna JO, Ray RA, Goldstein LJ, et al: Ol'thotopic liver transplantation for 
hepatobiliar}, malignancy. Transplantation 1986; 42:561-562. 
Curr Probl Surg, April 1990 ,2.33 
544. Starzl TE, Van Thiel 0, Tzakis AG, et al: Orthotopic liver transplantation for 
alcoholic cirrhosis. JAAtA 1988; 260:2542-2544. 
545. Starzl TE, Todo 5, GOI"don R, et al: Liver transplantation in older patients. N 
Engl J Med 1987: 316:484-485. 
546. Esquivel CO, Koneru B, Karrer F, et al: Liver transplantation under one year· 
of age. J Pediatr 1987; 110:545-548. 
547. Kalayoglu ~lI Slralta RJ, Sollinger HW, et al: Liver transplantation in infants 
and children. J Pediatr 1989; 24:70-76. 
548. Starzl TE, Iwatsuki S, Shaw BW, et al: Transplantation and other aspects of 
surgery of the liver, in Berk JE (ed-in-chief): Gastroenterology. Philadelphia, 
Saunders Co, vol 5, 1985, pp 3398-3448. 
549. Shiel AGR, Thompson JF, Stevens [viS, et al: Mesoportal gr·aft for throm-
bosed portal vein in liver transplantation. Clin Transplant 1987; 1:18-20. 
550. Tzakis A, Todo S, Stieber A, et al: Venous jump grafts for liver transplanta-
tion in patients with portal vein thrombosis. Transplantation 1989; 
48:530-531. 
551. Van Thiel DH, Hagler NG, Schade RR, et al: In vivo hepatic volume determi-
nation using sonography and computed tomography. Gastroenterology 
1985; 88:1812-1817. 
552. Terblanche J, llurroughs AK, Hobbs KEF: Controversies in the manage-
ment of bleeding esophageal varices. N Engl J Med 320:1393-1398, 1469-
1475. 
553. Iwatsuki 5, Stand TE, Todo S, et al: Liver transplantation in the treatment of 
bleeding esophageal varices. Surgery 1988; 104:697-706. 
554. Brems JJ, Hiatt JR, Klein AS, et al: Effect of a prior portasystemic shunt on 
subsequent liver transplantation. Ann Surg 1989; 209:51-56. 
SSS. Cuelvas-Mons V, Rimola A, Van Thiel OH, et al: Does previous abdominal 
surgery alter the outcome of pediatr·ie patients subjected to orthotopic 
liver transplantation? Gastroenterologv 1986; 90:853-857. 
556. Mazzaferro V, Todo S, Tzakis AG, et al: Liver transplantation in patients 
with previous portosystemic shunt procedures. Am J Surg (in press). 
557. Marsh JVV Jr, Iwatsuki 5, Makowka L, et al: Orthotopic liver transplantation 
for primary sclerosing cholangitis. Ann Surg 1988; 207:21-25. 
558. Ghent CN, Grant D, Bloch M, et al: SUI'gical portosystemic shunts do not 
influence outcome of orthotopic liver transplantation. A retrospective 
study. Clin Invest IvIed 1988; 11 :C49. 
559. Ostberg L, Purseh E: Human x imouse x human) hybridoma stably pro-
ducing human antibodies. Hybridoma 1983; 2:361-367. 
560. Lavivi Y, Grangeot-Keros L, Oelti-aissy J, et al: Reappearance of hepatitis B 
virus in immune patients infected with the human immunodeficiency vi-
ms type I. J Infect Dis 1988; 158:666-667. 
561. Seltman HJ, Dekker A, Van Thiel DH, et al: Budd-Chiari syndrome recurring 
in a transplanted liver. Gastroenterology 1983; 84:640-643. 
562. Schmid TH, Sandbichler P, Pernthaler H, et al: Multiple venous thrombosis 
with recurrence of Budd-Chiari syndrome after liveI· transplantation for 
paroxysmal nocturnal haematuria. (;/i11 Transplant 1989: 3:194-197. 
563. Campbell DA Jr, Rolles K, Jamieson N, et al: Hepatic transplantation with 
per-ioperative and long term anticoagulation as treatment for lludd-Chiari 
syndrome. Surg Gynecol Obstet 1988; 166:511-518. 
564. Neuberger J, Portmann B, MacDougall BRO, et al: Recurrence of primary 
biliary cirrhosis after liver transplantation. N Engl .J IVIed 1982; 306:1-4. 
234 Curr Prabl Surg, April 1990 
565. Polson RJ, Portmann B, Neuberger J, et al: Evidence for disease recurrence 
after liver transplantation for primaI)' biliary cirrhosis. Clinical and histo-
logic follow-up studies. Gastroenterology 1989; 97:715-725. 
566. Esquivel CO, Van Thiel DH, Demetris AJ, et al: Transplantation for primary 
biliary cirrhosis. GastroenteroloKv 1988; 94:1207-1216. 
567. Buist LJ, HubscheI' S, Vickers C, et al: Does liver transplantation cure pri-
mary biliary cirrhosis? Transplant Proc 1989; 21:2402. 
5.£8. Haagsma E, Manns M, Klein R, et al: Subtypes of antimitochrondrial anti-
bodies in primaI)' biliary cirrhosis before and after orthotopic liver trans-
plantation. Hepatology 1987; 7:129-133. 
569. Lerut J, Demetris N, Stieber AC, et al: Intrahepatic bile duct strictures after 
human orthotopic liver transplantation. Recurrence of primary sclerosing 
cholangitis or unusual presentation of allograft rejection? Transplant Int 
1988; 1:1-10. 
570. Neuberger J, Portmann B, Caine R, et al: Recurrence of autoimmune 
chronic active hepatitis following liver grafting. Transplantation 1984; 
37:363-365. 
571. L'age-Stehr J, Schwarz A, Offerman G, et al: HTLV-II1 infection in kidney 
transplant recipients. Lancet 1985; 2:1361-1362. 
572. Prompt CA, Reis MM, Grillo FM, et al: Transmission of AIDS virus at renal 
transplantation. Lancet 1985; 2:672. 
573. Dummer JS, Erb S, Breinig MK, el al: Infection with human immunodefi-
ciency virus in the Pittsburgh transplant population. A study of 583 donors 
and 1043 recipients 1981-1986. Transplantation 1989; 47:134-149. 
574. Centers for Disease Control: Human immunodeficiency virus infection 
transmitted from an organ donor screened for HIV antibody. MMWR 1987; 
36:306-308. 
575. Shaffer D, Pearl RH, Jenkins RL, et al: HTLV-II1/LAV infection in kidney and 
liver transplantation. Transplant Proc 1987; 19:2176-2178. 
576. Rubin RH, Jenkins RL, Shaw BW Jr, et al: The acquired immunodeficiency 
syndrome and transplantation. Transplantation 1987; 44:1-4. 
577. Tzakis AG, Cooper M, Starzl TE: Transplantation in HIV (+) patients. Trans-
plantation (in press). 
578. Osther K, Klintmalm G: The quick western blot, a novel transportable 50 
minute HIV-1 antibody test: Application in organ procurement for trans-
plantation. Transplantation 1989; 47:828-834. 
579. Allain TP, Laurian Y, Paul DA, et al: Serologic markers in early stages of hu-
man immunodeficiency virus infection in haemophiliacs. Lancet 1986: 
2:1233-1236. 
580. Trey C: The fulminant hepatic failure sUIveillance study: Brief review of the 
effects of presumed etiology and age on survival. Can Med Assoc J 1972; 
106:525-527. 
581. Trey C, Davidson CS: The management of fulminant hepatiC failure, in Pop-
per H, Schaffner F (eds): Progress in Liver Disease. New York, Grune & Strat-
ton, 1970, vol TTJ, pp 282-298. 
582. Bernuau J, Rueff B, Benhamou JP: Fulminant and sllbfulminant liver fail-
ures: definition and causes. Semin Liver Dis 1986; 6:97-106. 
583. Iwatsllki S, Esquivel CO, Gordon RD, et al: Liver transplantation for fulmi-
nant hepatic failure. Semin Liver Dis 1985; 5:325-328. 
584. Peleman R, Gavaler JS, Van Thiel DH, et al: Orthotopic liver transplantation 
for acute and subacute hepatic failure in adults. Hepatology 1987; 
7:484-489. 
Curr probl Surg, April 1990 .235 
585. Bismuth H, Didier S, Gugenheim J, et al: Emergency liver transplantation 
for fulminant hepatitis. Ann Intern Med 1987; 107:337-341. 
586. Stieber AC, Ambrosino G, Van Thiel D, et al: Orthotopic liver transplanta-
tion for fulminant and subacute hepatic failure. Gastroenterol Clin North 
Am 1988; 17:157-165. 
587. O'Grady JG, Alexander GJM, Thick M, et al: Outcome of orthotopic liver 
transplantation in the aetiological and clinical variants of acute liver failure. 
QJ Med 1988; 69:817-824. 
588. Ringe B, Pichlmayr R, Lauchart W, et al: Indications and results of liver 
transplantation in acute hepatic failure. TrallBplant Proc 1986; 18(suppl 
3):86-88. 
589. Brems JJ, Hiatt JR, Ramming KP, et al: Fulminant hepatic failure: The role of 
liver transplantation as primruy therapy. Am J Surg 1987; 154:137-141. 
590. Emond JC, Aran PP, Whitington PF, et al: Liver transplantation in the man-
agement of fulminant hepatic failure. Gastroenterology 1989; 96:1583-1588. 
591. Gallinger S, Blendis LM, Roberts E, et al: Liver transplantation for acute and 
subacute fulminant hepatic failure. Tra1JBplant Proc 1989; 21:2435-2438. 
592. Woodle ES, Moody RR, Cox KL, et al: Orthotopic liver transplantation in a 
patient with Amanita poisoning. JAMA 1985; 253:69-70. 
593. Christensen E, Bremmelgaard A, Bahnsen M, et al: Prediction of fatality in 
fulminant hepatic failure. Scand J GastroenteroI1984; 19:90-96. 
594. O'Grady JG, Alexander GJM, Hayllar KM, et al: Early indicators of prognosis 
in fulminant hepatic failure. Gastroenterology 1989; 97:439-445. 
595. Sinclair SB, Greig PD, Blendis LM, et al: Biochemical and clinical response 
of fulminant viral hepatitis to administration of prostaglandin E. J Clin In-
vest 1989; 84:1063-1069. 
596. Starzl TE, Gordon RD, Tzakis A, et al: Equitable allocation of extrarenal or-
gans: With special reference to the liver. Transplant Proc 1988; 20:131-138. 
597. Ghent CN: The liver transplant candidate: Assessment and followup, in 
Maddrey W (ed): Transplantation of the Liver. New York, Elsevier North-Hol-
land, 1988, pp 59-86. 
598. Starzl TE, Iwatsuki S, Shaw BW Jr, et al: Analysis of liver transplantation. 
Hepatology 1984; 4(suppl):47S-49S. 
599. Shaw BW Jr, Wood BP, Gordon RD, et al: Influence of selected patient vari-
ables and operative blood loss on six-month survival following liver trans-
plantation. Semin Liver Dis 1985; 5:385-393. 
600. Malatack JJ, Schaid DJ, Urbach AH, et al: Choosing a pediatric recipient for 
orthotopic liver transplantation. J Pediatr 1987; 111:479-489. 
601. Markus BH, Dickson ER, Grambsch PM, et al: Efficacy of liver transplanta-
tion in patients with primruy biliruy cirrhosis. N Engl J Med 1989; 
320:1709-1713. 
602. Neuberger J, Altman DG, Christensen E, et al: Use of a prognostic index in 
evaluation of liver transplantation for primary biliruy cirrhosis. Transplanta-
tion 1986; 41:713-716. 
603. Dickson ER, Grambsch PM, Fleming TR, et al: Prognosis in primary biliary 
cirrhosis: Model for decision making. Hepatology 1989; 10:1-7. 
604. O'Grady J, Williams R: Present position of liver transplantation and its im-
pact on hepatological practice. Gut 1988; 29:566-570. 
605. Miller C, Mazzaferro V, Makowka L, et al: Orthotopic liver transplantation 
for massive hepatic lymphangiomatosis. Surgery 1988; 103:490-495. 
606. Starzl TE: Surgery for metabolic liver disease, in McDermott WV (ed): 
236 
Surgery of the Liver Boston, Blackwell Scientific Publications, 1986 pp 127-
136. 
Curr Prabl Surg, April 1990 
607. Putnam CW, Porter KA, Peters RL, et al: Liver replacement for alpha-I-anti-
trypsin deficiency. Surgery 1977; 81:258-261. 
608. Hood JM, Koep LJ, PeteI'S RL, et al: Liver transplantation for advanced liver 
disease with alpha-I-antitrypsin deficiency. N Engl J Med 1980; 
302:272-275. 
609. Esquivel CO, Vicente E, Van Thiel D, et al: Orthotopic liver tmnsplantation 
for alpha-I-antitrypsin deficiency: An experience in 29 children and 10 
adults. Transplant Proc 1987; 19:3798-3802. 
610. Dubois RS, Giles G, Rodgerson DO, et al: Orthotopic liver transplantation 
for Wilson's disease. Lancet 1971; 1:505-508. 
611. Groth CG, Dubois RS, Corman J, et al: Metabolic effects of hepatic replace-
ment in Wilson's disease. Transplant Proc 1973; 5:829-833. 
612. Zitelli BJ, Malatack JJ, Gartner JC Jr, et al: Orthotopic liver transplantation 
in children with hepatic-based metabolic disease. Transplant Proc 1983; 
15 :1284-1287. 
613. Esquivel CO, Marino IR, Fioravanti V, et al: Liver transplantation for meta-
bolic disease of the liver. Gastroenterol Clin NorthAm 1988; 17:167-175. 
614. Sokol RJ, Francis PD, Gold SH, et al: Orthotopic liver transplantation for 
acute fulminant Wilson's disease. J Pediatr 1985; 107:549-552. 
615. Rakela J, Kurtz SB, McCarthy JT, et al: Fulminant Wilson's disease treated 
with postdilutional hemofiltration and orthotopic liver transplantation. 
Gastroenterology 1986; 90:2004-2007. 
616. Polson RJ, Rolles K, CaIne RY, et al: Reversal of severe neurological manifes-
tations of Wilson's disease following orthotopic liver transplantation. Q J 
Med 1987; 64:244, 685-691. 
617. Fisch RO, McCabe ERB, Doeden D, et al: Homotransplantation of the liver 
in a patient with hepatoma in hereditary tyrosinemia. J Pediatr 1978; 
93:592-596. 
618. Starzl TE, Zitelli BJ, Shaw BW Jr, et al: Changing concepts: Liver replace-
ment for hereditary tyrosinemia and hepatoma. J Pediatr 1985; 
106:604-606. 
619. Van Thiel DH, Gartner LM, Thorp FK, et al: Resolution of the clinical fea-
tures of tyrosinemia following orthotopic liver transplantation for he-
patoma. J Hepato11986; 3:42-48. 
620. Malatack JJ, Finegold DN, Iwatsuki S, et al: Liver transplantation for type I 
glycogen storage disease. Lancet 1983; 1:1073-1076. 
621. Cox KL, \Vard RE, Furgiuele TL, et al: Orthotopic liver transplantation in 
patients with cystic fibrosis. Pediatrics 1987; 80:571-574. 
622. Mieles LA, Orenstein D, Teperman L, et al: Liver tmnsplantation in cystic 
fibrosis. Report of 9 cases from the University of Pittsburgh. Lancet 1989; 
1:1073. 
623. Daloze P, Delvin EE, Glorieux JH, et al: Replacement therapy for inherited 
enzyme deficiency. Liver replacement in Niemann-Pick disease type A. Am 
J Med Genet 1977; 1:229-239. 
624. Gartner JC Jr, Bergman I, Malatack JJ, et al: Progression of neurovisceral 
storage disease with supranuclear ophthalmoplegia following orthotopic 
liver transplantation. Pediatrics 1986; 77:104-106. 
625. Samuel D, Boboc B, Bernuau J, et al: Liver transplantation for protoporphy-
ria. Evidence for the predominant role of the erythropoietic tissue in pro-
toporphyria overproduction. Gastroenterology 1988; 95:816-819. 
626. Polson RJ, Lim CK, Rolles K, et a1: The effect of liver tmnsplantation in a 13 
year old boy with erythropoietic protoporphyria. Transplantation 1988; 
46:386-389. 
Curr Probl Surg, April 1990 237 
627. Wolff H, Otto G, Giest H: Liver transplantation in Crigler-Najjar syndrome. A 
case report. Transplantation 1986; 42:84. 
628. Kaufman SS, Wood RP, Shaw BW Jr, et al: Orthotopic liver transplantation 
for type I Crigler-Najjar syndrome. Hepatology 1986; 6:1259-1262. 
629. Watts RW, CaIne RY, Rolles K, et al: Successful treatment of primaly hyper--
oxaluria type I by combined hepatic and renal transplantation. Lancet 
1987; 2:474-475. 
630. Todo S: Personal communication, 1~gU9K 
631. Casella JF, Lewis JH, Bontempo FA, et al: Successful treatment of homozy-
gous protein C deficiency by hepatic transplantation. Lancet 1988; 
1:435-438. 
632. Starzl TE, Bilheimer DW, Bahnson liT, et al: Heart-liver transplantation in a 
patient with familial hypercholesterolaemia. Lancet 1984; 1 :1382-1383. 
633. Bilheimer DW, Goldstein JL, Grundy SM, et al: Liver transplantation to pro-
vide low-density-lipoprotein receptors and lower plasma cholesterol in a 
child with homozygous familial hypercholesterolemia. N Engl J Med 1984; 
311 :1658-1664. 
634. Hoeg JM, Starzl TE, Brewer JB Jr: Liver transplantation for the treatment of 
cardiovascular disease: Comparison with medication and plasma exchange 
in homozygous familial hypercholesterolemia. Am J Cardiol 1987; 
59:705-707. 
635. Mora NP, Cienfuegos JAo Ardaiz J, et al: Operative events in the first case of 
liver grafting after heart transplantation. Surgery 1988; 103:264-267. 
636. Lewis JH, Bontempo FA, Spero JA, et al: Liver transplantation in a hemo-
philiac. N Engl J Med 19S5; P1O:11U9-11~1MK 
637. Bontempo FA, Lewis JH, Gorenc TJ, et al: Liver transplantation in hemo-
philia A. Blood 1987; 69:1721-1724. 
638. Gibas A, Dienstag JL, Schafer AI, et al: Cure of hemophilia A by orthotopic 
liver transplantation. Gastroenterology 1988; 95:192-194. 
639. Merion RM, Delius RE, Campbell DA Jr, et al: Orthotopic liver transplanta-
tion totally corrects factor IX deficiency in hemophilia B. Surgery 1988; 
104:929-931. 
640. Alper CA, Johnson AM, Birtch AG, et al: Human C3: Evidence for the liver as 
the primary site of synthesis. Science 1969; 163:286-288. 
641. Alper CA, Raum D, Awdeh Z, et al: Studies of hepatic synthesis in vivo of 
plasma proteins, including orosomucoid, transferrin, alpha-I-antitrypsin, 
C8, and factor B. Clin Immunol Immunopathol1980; 16:84-89. 
642. Raum D, Marcus D, Alper CA, et al: Synthesis of human plasminogen by the 
liver. Science 1980; 208:1036-1037. 
643. Wolpl A, Robin-Winn M, Pichlmay" R, et al: Fourth component of comple-
ment (C4) polymorphism in human orthotopic liver transplantation. Trans-
plantation 1985; 40:154-157. 
644. Wolpl A, Lattke H, Board PG, d al: Coagulation factor XIIIA. Transplantation 
1987; 43:151-153. 
645. Hobart MJ, Lachmann PJ, CaIne RY: Synthesis by the liver in vivo. J Ex.p 
Med 1977; 146:629-630. 
646. Uzik WJ, Arkin CF, Jenkins RL: Transfer of congenital factor XI deficiency 
from donor to recipient as a I"esull of liver transplantation. N Engl J Med 
1987; 316:1217-1218. 
647. Parkman R: The application of bone marrow transplantation to the treat-
ment of genetic diseases. Science 1986; 232:1373-1378. 
648. Margreiter R, Kramar R, Huber C, et al: Combined liver and kidney trans-
plantation. Lancet 1984; 1:1077-1078. 
238 Curr Prabl Surg, April 1990 
649. Gonwa TA, Nery JR, Husbert BS, et al: Simultaneous liver and renal trans-
plantation in man. Transplantation 1988; 46:690-693. 
650. Rakela J, Kurtz SB, McCarthy IT, et al: Fulminant Wilson's disease treated 
with postdilution hemofiltration and orthotopic liver transplantation. Gas-
troenterology 1986; 90:2004-2007. 
651. Vogel W, Steiner E, Komberger R, et al: Preliminary results with combined 
hepatorenal allografting. Transplantation 1988; 45:491-493. 
652. Shaw BW Jr, Bahnson HT, Hardesty RL, et al: Combined transplantation of 
the heart and liver. Ann Surg 1985; 202:667-672. 
653. Wallwork J, Williams R, Calne RY: Transplantation of the liver, heart, and 
lungs for primary biliary cirrhosis and primary pulmonary hypertension. 
Lancet 1987; 2:182-185. 
654. Starzl TE, Rowe MI, Todo S, et al: qransplantatill~ of multiple abdominal 
viscera. JAMA 1989; 261:1449-1457. 
655. Williams JW, Sankary HN, Foster PF, et al: Splanchnic transplantation-an 
approach to the infant dependent on parenteral nutrition who develops ir-
reversible liver disease. JAMA 1989; 261:1458-1462. 
656. Shaffer Dj Maki T, DeMichels SJ, et al: Studies in small bowel transplanta-
tion. Prevention of graft versus host disease with preservation of allograft 
function by donor pretreatment with antilymphocyte serum. Transplanta-
tion 1988; 45:262-269. 
657. Starzl TE, Todo S, Tzakis A: Abdominal organ cluster transplantation for 
the treatment of upper abdominal malignancies. Ann Surg 1989; 
210:374-386. 
658. Starzl TE, Koep LJ, Schroter GPJ, et al: The quality of life after liver trans-
plantation. Transplant Proc 1979; 11:252-256. 
659. Starzl TE, Iwatsuki S, Malatack JJ, et al: Liver and kidney transplantation in 
children receiving cyclosporin A and steroids. J Pediatr 1982; 100:681-686. 
660. Zitelli BJ, Miller JW, Gartner JC Jr, et al: Changes in life style after liver 
transplantation. J Pediatr 1988; 82:173-180. 
661. Urbach AH, Gartner JC Jr, Malatack JJ, et al: Linear growth following pedi-
atric liver transplantation. Am J Dis Child 1987; 141:547-549. 
662. Tarter RE, Erb S, Biller P, et al: The quality of life following liver transplan-
tation: A preliminary report. Gastroenterol Clin North Am 1988; 17:207-217. 
663. Iwatsuki S, Shaw BW Jr, Starzl TE: Five-year survival after liver transplanta-
tion. Transplant ?roc 1985; 17:259-263. 
664. Starzl TE, Marchioro TL, Rowlands DT Jr, et al: Immunosuppression after 
experimental and clinical homotransplantation of the liver. Ann Surg 1964; 
160:411-439. 
665. Marchioro TL, Porter KA, Dickinson TC, et al: Physiologic requirements 
for auxiliary liver homotransplantation. Surg Gynecol Obstet 1985; 121: 
17-31. 
666. Starzl TE, Francavilla A, Halgrimson CG, et al: The origin, hormonal nature, 
and action of hepatotrophic substances in portal venous blood. Surg Gyne-
col Obstet 1973; 137:179-199. 
667. Fortner JG, Yeh SDJ, Kim DK, et al: The case for and technique of hetero-
topic liver grafting. Transplant ?roc 1979; 11:269-275. 
668. Fortner JC, Kinne DW, Shiu MH, et al: Clinical liver heterotopic (auxiliary) 
transplantation. Surgery 1973; 74:739-751. 
669. Starzl TE, Groth C, Makowka L: Clio chirurgica, in Landes RG (ed): Liver 
Transplantation. Austin, Texas, Silvergirl, 1988. 
670. Houssin D, Franco D, Berthelot P, et al: Heterotopic liver transplantation in 
end-stage HBsAG positive cirrhosis. Lancet 1980; 1:990-993. 
Curr Prabl Surg, April 1990 239 
671. Terpstra OT, Reuvers CB, Schalm SW: Auxiliary heterotopic liver transplan-
tation. Transplantation 1988; 45:1003-1007. 
672. Terpstra OT, Schalm SW, Weimar W, et al: Auxiliary partial liver transplan-
tation for end-stage chronic liver disease. N Engl J Med 1988; 
319:1507-1511. 
673. Ol'gan Donation is Increasing in the United States: United Network for Or-
gan Sharing update, 1989; 5:1-5. 
674. Bismuth H, Ericzon BG, Rolles K, et al: Hepatic transplantation in Europe. 
First report of the European Transplant Registry. Lancet 1987; 2:674-676. 
675. Darby JM, Stein KL, Grenvik A, et ali Management of the brain dead organ 
donor in the intensive care unit . .lAMA 1989; 261:2222-2228. 
676. Popper H: Hepatology, coming of age.llepatology 1985; 5:1224-1226. 
677. Teperman L, Podesta L, Mieles L, et al: The successful usc of older donors 
for liver transplantation. JAMA 1989; 262:2837. 
678. Report of the Task Force on Liver Transplantation in Massachusetts. Blue 
Crol;S and Blue Shield, Massachusetts, May 1983. 
679. Stm'zl TE, Shapiro R, Teperman L: The point system for organ distribution. 
Transplant Proc 1989; 21:3432-3436. 
680. O'Donnell TF, Gembarowicz RM, Callow AD, et ali The economic impact of 
acute variceal bleeding: Cost-effectiveness implications for medical and 
surgical therapy. Surgery 1980; 88:693-701. 
681. Evans RW: Cost-effectiveness analysis of transplantation. Surg Clin North 
Am 1986; 66:603-615. 
682. Williams JW, Vera S, Evans LS: Socioeconomic aspects of hepatic transplan-
tation. Am J Gastroenterol1987; 82:1115-1119. 
683. Brass A: Surgery runs amok. l\'led J AlISt 1984; 141:330. 
684. Starzl TE: Liver transplantation in Australia. Med J Aust 1987; 147:369. 
685. Sheil AGR, Thompson JF, Gallaghel' ND, et al: Initial report of the Australian 
National Pilot Liver Transplantation Programme. Med J AlISt 1987; 
147:372-380. 
686. Lynch S, Kerlin P, Wall D, et al: The Queensland liver transplant pro-
gramme: The first two years. Med J Aust 1987; 147:380-385. 
687. Teperman L, Scantlebury V, Tzakis A, et al: Liver transplantation in black 
recipients: Pittsburgh. Transplant Proc 1989, 21:3963-3965. 
240 Curl' Prabl Surg, April 1990 
To Subscribe: 
Simply fill out this coupon and 
send it to us at the address 
sho\vn. 
Or, 
for faster service, call our 
TOLL-FREE numher: 
1-800-622-5410 
(In Illinois. please call collect 
312-726-9746) 
Prepaid order.; are _,mpp<'d 1""l"W' fre,- .1<1<.] H 'i() per order '0 
~Dtter h:andhnij_ OIner onJe" ",II t><e hiil~d A shjppjog and 
handling <;lur!lt'_ II MA. Tr-. re"dents w,ll r.,. billed appropriate 
"""-,,, I!IX mnnD~ If>: 'lUUI<.,j Ul l ~_ clolIM' C"n~<l;"n or<l,'" will 
he 1>,11",1 Ln Ctn.lJ",n funds a{ {he nmen! eD"-h""~e fJle Ali 
pri(e, D1ih~-ED 10 Eh~nge w,moul notl<:c 
Let our eminent medical 
authorities guide you through 
major new clinical advances 
Introducing the 
Year Book of 
Surgery® 
This time-saving guide book makes it 
easy for you to keep current in your field. 
Each volume represents the year's most significant 
developments as reported in more than 800 journals and 
periodicals published worldwide. These selections are 
condensed to roughly a page in length, so you get all 
essential facts at a glance. 
More importantly, the distinguished physician editors provide 
thoughtful, probing commentaries that explore the 
significance of each article while evaluating its practical 
implications for (by-to-day practice. 
Save hours of reading and research time and get expert 
guidance with this invaluable reference! 
rl1<"'" bo<.>k, g<~ pubh,hed ~nnu:altyI for the {""ven1<',,,"" of ,I., ,u'>tome,.". Year Book eme", each pure"""" as, M10'c11Der to future volUIlle!> 
.1m] ",,'nd, ~nnll~1 .nnouncemernsofcach volume appInu"D1a!ef~ two months before publication. The ne", ',,'umc w,!! t><: ,luprcJ uporl 
puhllca{,on uflle" you cOlllplett;' and re(um the cm;cdtaHon .. olitt auad",,J 10 tbe annouf'K"emenl ~nd iI" rIIE~<v .. d by Year B<'OK within tht> lime 
fnd"~Ded EarproxDmKlf~ly .lOdayb after your receipt of Ih~ . ..,oouncememl You may Clncel your subsoipnon at .. n,' Ilme The ly~w volume may 
he n,'m,n"d on .. ppr"D~~t for 30 dK~K1>E1 returned fo, full ereJ;! Yea, Book ",,11 remove your IllIme as" >uhst-r,h,,, o~lum po".ge i., 
gu.r.ntt"I:<J hy Y'"Af l:Ionk loll", 1",,,],11 ""III-iI~ 
1.-----------------------1 
[Xl YES! I 
I know it's vital that r stay informed. Please rush me the most recent issul' of I 
the Year Book ojSurgerl' (2-89) for $51.9'). 
LJ Paymem Enclosed LJ Please bill me 0 Charge my AmexIVisa/MastcrCard (drde one) I 
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Account Number/Expirarion Date 
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- -------
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Telephone X14 
Mail to: 
Mosby-Year Book Inc-
200 Nonh laSalle Street, Chicago. IL 60601 L _______________________ ~ 

